Cumulative Index 1982-1984

Note: The volume year is in *italic* type. Page numbers of symposia and article titles are in **boldface** type.

SYMPOSIA

1982

March Blood Banking and Hemotherapy

Iune RESPIRATORY INFECTIONS

September LABORATORY MEASUREMENTS IN MALIGNANT DISEASE

December Test Selection Strategies

1983

March Computers in the Clinical Laboratory

June FORENSIC PATHOLOGY
September LABORATORY MANAGEMENT
December TISSUE IMMUNOPATHOLOGY

1984

March Controversies in Laboratory Medicine

Iune COAGULATION

September Environmental and Occupational Health Hazards

December Issues in Laboratory Endocrinology

ABO incompatibility, crossmatch and, 1982: Mar., 190

in hemolytic disease of newborn, 1982: Mar., 110–116

transfusion reactions and, 1982: Mar., 229–230

ABO matching, in emergency cardiovascular surgery, 1982: Mar., 78-81

ABO-Rh compatibility, in pretransfusion testing, 1982: Mar., 169-179

ABO-Rh typing, in hemolytic anemia, 1982: Mar., 195–198 ABO system, 1982: Mar., 141

ABO typing, in emergency transfusion,

1982: Mar., 78–81 Abortions, spontaneous, repeated, chromosomal abnormalities in, cytogenetic

evaluation, 1984: Dec., 841–842 Abuse. See Child abuse.

Accident(s), drug use and, 1983: June, 306, 379-380

hit-and-run, collection of evidence in, 1983: June, 357, 364

Accident reports, 1983: Sept., 476

Accuracy, in quality control studies, 1983: Sept., 548

Acetylsalicylic acid, affect on inflammatory response, 1983: Dec., 706

Acid-fast stain(s), in tuberculosis, 1982: June, 311–312

Acquired immunodeficiency syndrome (AIDS), common immunologic abnormalities seen with, 1984: June, 334

in hemophiliacs, 1984: June, 333–344 immune abnormalities and laboratory findings in, 1984: June, 338–340

Activated partial prothrombin time (APPT), 1984: June, 221

Activated partial thromboplastin time (APTT), 1984: June, 295

Adenomas, pituitary, 1984: Dec., 643–654 Adrenocorticotropic hormone, ectopic, 1984: Dec., 775–778

measurement of, in hypercortisolism, 1984: Dec., 693-696

hypersecretion of by pituitary adenomas, 1984: Dec., 650–651

in regulation of cortisol secretion, 1984: Dec., 684–686

mass effects of pituitary tumors on, 1984: Dec., 645-646

Adsorption, of toxic compounds in the environment, 1984: Sept., 454-456

Adult respiratory distress syndrome. See Respiratory distress syndrome, adult. Age, chlamydial respiratory infection and, 1982: June. 372–375

Agglutination, of red blood cells, 1982: Mar., 155-167

AIDS. See Acquired immunodeficiency syndrome.

Airflow obstruction, chronic, emphysema and, 1984: Sept., 548–550

and, 1984: Sept., 548-550 Albumin, erythrocyte agglutination and, 1982: Mar., 165-166

fluid therapy and, 1982: Mar., 50–52 Alcohol, beverage, defined, 1983: June, 385–386

effect on CEA clearance, 1982: Sept., 459-467

ethyl, blood levels of, 1983: June, 383 in fire victims, 1983: June, 306 metabolism of, 1983: June, 388–389 poisoning by, 1983: June, 385–396

ingestion of by children, 1984: Sept., 595 Aldosteronism, primary, test selection in, 1982: Dec., 795–796

Algorithms, in diagnostic process, 1984: Mar., 7

Alkaline phosphatase, in assessment of bone metabolism, 1984: Dec., 767–768

Allergic reaction(s). See *Anaphylaxis*. Alloantibody(ies), detection, in autoimmune hemolytic anemia, 1982: Mar., 199–203 removal, by plasma exchange, 1982: Mar., 94–95

Allograft, rejection, mechanisms of, 1983: Dec., 764–765

Alpha₂-antiplasmin assay, synthetic substrate for, 1984: June, 391

Alpha-fetoprotein, in germ cell tumors, 1982: Sept., 435–440

Aluminum, neurotoxicity of, 1984: Sept., 491–493

Alzheimer's disease, aluminum and, 1984: Sept., 492

Amenorrhea, 1984: Dec., 720-723

American Association of Blood Banks, 1983: Sept., 448

Ammunition. See also Bullets; Cartridges. historical development of, 1983: June, 259–260, 274–277

ANA. See Antinuclear antibody.

Anbabolic steroids, increased antithrombin III deficiency with, 1984: June, 263 Anaerobe(s), isolation of, 1982: June,

297-298 susceptibility testing of, 1984: Mar., 109

Anaerobic bacteria, in pleuropulmonary infection, 1982: June, 285–303

Anaerobic culture, collection, and handling

of specimens for, 1983: Sept., 534 Anaerobic systems, in respiratory infection, 1982: June, 298

Anaphylaxis. See also Inflammatory response.

mediators of, 1983: Dec., 619-643 Anaphylatoxin. See Complement.

Anatomic pathology, computer information systems in, 1983: Mar., 133–147 laboratory, 1983: Sept., 477

Anemia, autoimmune hemolytic, transfusion in, 1982: Mar., 193–210 iron deficiency, laboratory evaluation of,

iron deficiency, laboratory evaluation of, 1982: Dec., **751–777** Angiodysplasia, in von Willebrand's disease,

1984: June, 311 Angiotensin converting enzyme, in endo-

toxin-induced lung injury, 1983: Dec., 731 subcellular sites of, 1983: Dec., 581–583

Ankylosing spondylitis, HLA-B27 antigen and, 1982: Mar., 130-131

Antibiotics, bleeding due to, 1984: June, 238 for antimicrobial susceptibility testing,

1984: Mar., 101–105 minimum bactericidal concentrations of, 1984: Mar., 111

1964: Mar., 111 tolerance to, 1984: Mar., 112

Antibody(ies). See also Immunoglobin(s). antiglobulin test and, 1982: Mar., 176, 186–191

blood group of, 1982: Mar., 79

cell destruction and, 1982: Mar., 211–219 detection, by laboratory techniques, 1983: Dec., 757–760

in *Pneumocystis* infection, 1982: June, 403–404

monoclonal, in autoimmune disorders, 1983: Dec., 759–760

in organ transplantation, 1983: Dec., 777

Antibody marker(s), of connective tissue disease, 1983: Dec., 754–757
of endocrine disease, 1983: Dec., 750–753
of liver disease, 1983: Dec., 749–750
of muscular disease, 1983: Dec., 753
of skin disease, 1983: Dec., 753

of thyroid disease, 1983: Dec., 750-752

Antibody-gel technique, in immunoassays, 1984: June, 347–348 Antibody neutralization, in estimation of

Factor VII antigen, 1984: June, 233, 234 Antibody screening, 1982: Mar., 112-113

Antibody screening, 1982: Mar., 112–113 in pretransfusion testing, 1982: Mar., 169–179, 181–192

Anticoagulant(s), circulating, test for, 1984:
June, 297

in blood storage, 1982: Mar., 4-6, 22-25 lupus, protein C and, 1984: June, 272

Anticoagulant therapy, in antithrombin III deficiency, 1984: June, 260 laboratory control of, fibrinopeptide A as-

says in, 1984: June, 375–377 Anti-D antigen, Rh immunization and, 1982:

Mar., 111-113
Antidiuretic hormone, secretion and action of, functional tests of, 1984: Dec.,

737–742 Antidotes, 1984: Sept., 621–624

Antigen(s), blood group, in breast cancer, 1982: Sept., 545-546

carcinoembryonic, in breast cancer, 1982: Sept., 550–555. See also Carcinoembryonic antigen.

erythrocyte, in autoimmune hemolytic anemia, 1982: Mar., 198–199

Factor VII, radioimmunoassay of, 1984: June, 233

high incidence types, 1982: Mar., 145-146

HLA, 1982: Mar., 123–135 disease associations and, 1982: Mar., 130–132; 1983: Dec., 747–748

in hemostasis, immunoassays for, 1984: June, 348–351

Kell type, in hemolytic disease of newborn, 1982: Mar., 111

low incidence types, 1982: Mar., 144–145 matching, in renal transplantation, 1982: Mar., 125–129

shared, 1982: Mar., 147-148

tumor-specific, in breast cancer, 1982: Sept., 544

viral cross-reactive, in breast cancer, 1982: Sept., 546–547

Antiglobulin test, direct vs. indirect, 1982: Mar., 199-200

in crossmatch, 1982: Mar., 176, 186–191 Antimicrobial agent(s), in anaerobic respiratory infection, 1982: June, 300–301

Antimicrobial susceptibility testing, antibiotics for, 1984: Mar., 101-105

controversies in, 1984: Mar., 99-121 direct and mixed, 1984: Mar., 116 disc vs. MIC procedures, 1984: Mar.,

107-109 interpretation of, 1984: Mar., 105-107 organisms requiring, 1984: Mar., 100

quality control of, 1984: Mar., 115 rapid, 1984: Mar., 117

Antinuclear antibody assays, in diagnosis of occupational lung disease, 1984: Sept., 531–532

Antinuclear antibody test, fluorescent, in SLE, 1982: Dec., 881–884

Antithrombin BM, 1984: June, 247 Antithrombin III, activity of, oral contraceptives and, 1984: June, 262

assays of, functional, 1984: June, 263–265 synthetic substrates for, 1984: June, 388–389

clinical disorders involving, 1984: June, 255–259, 261–263

clinical evaluation of, 1984: June, 265 decreased production of, 1984: June, 261–262

decreased survival of, 1984: June, 262-263

deficiency of, anticoagulant therapy for, 1984: June, 260 hereditary, 1984: June, 252, 256–257 patterns of, 1984: June, 257–259 pregnancy and, 1984: June, 260

surgery and, 1984: June, 260 tests for, 1984: June, 258 therapy for, 1984: June, 259–261 functional domains of, 1984: June,

247–248 immunoassay of, 1984: June, 265–266,

in cancer patients, 1982: Sept., 607 in hypertensive complications of pregnancy, 1982: Dec., 755–756

in liver disease, 1984: June, 426 inactivation of thrombin by 1984.

inactivation of thrombin by, 1984: June, 248–250

increased levels of, 1984: June, 261–263 interaction with heparin, 1984: June, 247, 249–251

interaction with serine proteases, 1984: June, 254–255 Antithrombin III (Continued)

laboratory evaluation of, 1984: June, 263-265

mechanism of action of, 1984: June, 249 molecular biology of, 1984: June, 247–255 purification of, 1984: June, 248 structure of, 1984: June, 247–248

synthesis of, L-asparaginase and, 1984: June, 262

APPT. See Activated partial prothrombin time.

APTT. See Activated partial thromboplastin time.

APUD cells, in carcinoid syndrome, 1984: Dec., 804–805

Arachidonic acid, metabolic pathways of, 1983: Dec., 623–624, 698

metabolism, macrophage activation and, 1983: Dec., 677-694

metabolites. See also specific substances, as Prostaglandin(s); Leukotriene(s). in endotoxin-induced lung injury, 1983: Dec., 724–729

in inflammatory response, 1983: Dec., 684–685

in neutrophil-mediated lung injury, 1983: Dec., 609–611

ARDS. See Respiratory distress syndrome, adult.

Arginine vasopressin, ectopically produced, 1984: Dec., 779–780

in water metabolism, 1984: Dec., 729–737 radioimmunoassays for, 1984: Dec., 732–737

Art materials, ingestion of, 1984: Sept., 592 Arthritis. See also Inflammatory disease(s). prostaglandins and, 1983: Dec., 704–706 rheumatoid, antibody markers of, 1983: Dec., 754–757

arachidonate metabolites and, 1983: Dec., 685-689

ARTHUR program, applications in test selection, 1982: Dec., 737, 741–742

Arthus reaction, prostaglandins and, 1983: Dec., 706

Asphyxiation, in electrical deaths, 1983: June, 348

in infants, vs. sudden infant death, 1983: June, 338–342

Aspiration, anaerobic infection and, 1982: June, 287

percutaneous lung, in respiratory infection, 1982: June, 278–279

transtracheal, in anaerobic respiratory infection, 1982: June, 292–293 in respiratory infection, 1982: June,

271–273 Aspiration cytology, diagnostic accuracy of, 1984: Mar., 91

limitations and value of, 1984: Mar., 89–98

Aspirin, in prostaglandin inhibition, 1984: Dec., 789

Assay(s). See under specific types.

Assent, Newman's grammar of, 1984: Mar., 12-14

Asthma, anaphylactic mediators and, 1983: Dec., 628

occupational, skin testing for, 1984: Sept., 523-526

Audit control, of laboratory information system, 1983: Mar., 176

Autacoid(s), in anaphylaxis, 1983: Dec., 619-620

Autoantibody(ies), in autoimmune hemolytic anemia, 1982: Mar., 194–195

removal, by plasma exchange, 1982: Mar., 92-94

specificity, 1982: Mar., 203-205

Autoimmune disorder(s), associated HLA antigens and, 1983: Dec., 747–748 laboratory diagnosis of, 1983: Dec.,

745–761
Autoimmune hemolytic anemia, transfusion in, 1982: Mar., 193–210

Autoimmunity, theories of development, 1983: Dec., 745–747

Automation. See Computer information systems.

Automobile(s), defective design, product liability and, 1983: June, 403

Automobile-related deaths, pathologist's role, 1984: Sept., 633-634

Autoprothrombin ÎIa, 1984: June, 266
Autopsy, controversy over, 1984: Mar., 166
in electrical deaths, 1983: June, 348–349

in explosion deaths, 1983: June, 317–318 in fire deaths, 1983: June, 298–306

in medical quality assurance, 1984: Mar., 165–184

in product liability deaths, 1983: June, 399–400

rates of, impact on resource utilization, 1984: Mar., 180-182

toxicologic analysis in, 1983: June, 368–370, 392–395

traditional concept of, 1984: Mar., 166–171

Avidin-biotin complex method, in detection of autoantibodies, 1983: Dec., 758–759

B cell(s). See Lymphocyte(s).

Backups, for software, in laboratory information system, 1983: Mar., 171–172

Bacteria, anaerobic, in pleuropulmonary infection, 1982: June, 285–303

Bactericidal dilution test, 1984: Mar., 112 Ballistics, wound, 1983: June, 260–261

Bands microscopic definition of, 1984: Mar., 72-75 Bartter's syndrome, prostaglandins and, 1984: Dec., 792

Baseline measurements, for hypercortisolism, 1984: Dec., 686–687
BASIC, 1983: Mar., 4, 7. See also Program-

ming languages.

Battered child, 1983: June, 321–342. See also Child abuse.

Batteries, ingestion of, 1984: Sept., 597 Bayes' theorem, 1982: Dec., 754

in classification of data, 1982: Dec., 729 in multiple testing, 1982: Dec., 875–876 variations, 1982: Dec., 687–690

Benzene, occupational exposure to, setting standards for, 1984: Sept., 477–479 Biodynamic models in test selection, 1982:

Biodynamic models, in test selection, 1982: Dec., 701–715

Biologic monitoring, for toxic chemicals, 1984: Sept., 502–505

Biomedical products, defective design, liability and, 1983: June, 403–404

Biopsy, aspiration, limitations and value of, 1984: Mar., 89–98. See also Aspiration cytology.

lung, in *Pneumocystis* infection, 1982: June, 395–396

open lung, in respiratory infection, 1982: June, 279–280

transbronchial lung, in respiratory infection, 1982: June, 275–276

Blast. See *Bombing(s)*; *Explosion(s)*. Bleaches, ingestion of, 1984: Sept., 593 Bleeding, antibiotic-induced, 1984: June,

238
excessive, laboratory evaluation of, 1984:
June, 285–301

Bleeding disorders, diagnosis of, history and physical examination in, 1984: June, 287-289

follow-up tests for, 1984: June, 290–292 laboratory evaluation of, 1984: June, 285–301

screening tests for, 1984: June, 289–290 Bleeding patient, laboratory evaluation of, 1984: June, 285–301

Bleeding time, 1984: June, 293–294 in von Willebrand's disease, 1984: June, 305

platelet-type, 1984: June, 320 Blood, alcohol levels, 1983: June, 386–395 in fire victims, 1983: June, 306 as evidence, collection of, 1983: June,

360–362 drug levels, 1983: June, 369, 371, 380–383

in electrical injury, 1983: June, 346 whole. See Whole blood.

Blood bank(ing), automated systems in, 1983: Mar., 111–132 inventory levels, 1982: Mar., 169–170 symposium on, 1982: Mar., 3–252 Blood cell(s). See Erythrocyte(s) or Leukocyte(s).

Blood clotting, pathways of, 1984: June, 207. See also Coagulation pathways.

Blood components, conservation, 1982: Mar., 69-72

in hemotherapy, 1982: Mar., 3-19 transfusion, in cardiovascular surgery, 1982: Mar., 75-82

Blood cultures, preanalytic factors in, 1983: Sept., 532

Blood donor, screening, 1982: Mar., 243–245

selection, 1982: Mar., 183–184 in autoimmune hemolytic anemia, 1982: Mar., 205–207

Blood factor assays, 1984: June, 296. See also specific factors.

Blood gas(es), collection and handling of specimens for, 1983: Sept., 525

Blood group(s), recent advances in, 1982: Mar., 137-154

Blood group antibodies, 1982: Mar., 79. See also Antibody(ies).

Blood group antigen(s), in breast cancer, 1982: Sept., 545–546

Blood group loci, chromosomal linkage of, 1982: Mar., 137–141

Blood platelet(s). See *Platelet(s)*. Blood poisoning. See *Septicemia*.

Blood pressure, elevated. See *Hypertension*. Blood products, federal regulation of, 1983: Sept., 444

labeling, in automated blood bank, 1983: Mar., 118–120, 123

Blood storage, 1982: Mar., 4–6, 22–25
Blood storage, 1982: Mar., 4–6, 22–25
Blood transfusion, See Fruthrocute transfusion

Blood transfusion. See Erythrocyte transfusion; Platelet transfusion: Transfusion. Blood typing, in pretransfusion testing,

1982: Mar., 169-179. See also ABO incompatibility.

Blood volume, deficiency, fluid therapy in, 1982: Mar., 55-56 Blunt injury, in battered child, 1983: June,

329–330 Body water, regulation of, hormonal disor-

ders of, 1984: Dec., 729–744

Bombing(s). See also Explosion(s).

explosive, injuries from, 1983: June, 304–305

injuries from, 1983: June, 314–316 Bone, aspiration biopsy of, 1984: Mar., 96

fracture. See Fracture(s).

mineral content of, measurement of, 1984: Dec., 771–772

resorption, prostaglandins and, 1983: Dec., 703

tumors, hydroxyproline in, 1982: Sept., 537

Bone biopsy, in assessment of bone metabolism, 1984: Dec., 771

Bone disease, osteopenic, laboratory evaluation of, 1984: Dec., 763-774

Bone marrow, aspiration biopsy of, 1984: Mar., 96

CK₁ activity in, 1982: Sept., 500

Bovine thromboplastin, quantitation of activated Factor VIIa by, 1984: June, 233

Bradykinin, in endotoxin-induced lung injury, 1983: Dec., 730–731

Brain, aspiration cytology of, 1984: Mar., 90 Brain injury, in battered child, 1983: June, 333–334

Breast, aspiration biopsy of, 1984: Mar., 94 cancer, CK₁ activity in, 1982: Sept., 499 hydroxyproline in, 1982: Sept., 523–528 laboratory measurements in, assessment of, 1982: Sept., 657–678 screening for, 1982: Sept., 646

tumor markers for, 1982: Sept., 543–565

Bromsulphalein test, hepatic function and, 1982: Dec., 708–709

Bronchoalveolar lavage (BAL), in respiratory infection, 1982: June, 276–277

Bronchoscopy, in anaerobic respiratory infection, 1982: June, 293–294 in respiratory infection, 1982: June, 273–275

Bruise(s), patterned, in battered child, 1983: June, 328–329

Bullet(s). See also Cartridge(s). kinetic energy of, 1983: June, 260–261 rifle, characteristics of, 1983: June, 261–264

velocity of, effect on tissue injury, 1983: June, 278

Bullet wounds. See Firearm wounds. Burn(s), electrical, 1983: June, 344–346 extent of, estimation of, 1983: June, 301 from explosions, 1983: June, 316 in battered child, 1983: June, 30–332 in bombing victims, 1983: June, 305 in fire victims, 1983: June, 300–303 inflammatory response in, 1983: Dec., 801–815

C-peptide, measurement of, in diabetes and hypoglycemia, 1984: Dec., 751

Calciferol. See Vitamin D.

Calcitonin, ectopic, as tumor marker, 1984: Dec., 782

Calcium, disorders, laboratory evaluation of, 1982: Dec., 809–812

in neutrophil stimulation, 1983: Dec., 781, 784–785

measurements of, in assessment of mineral metabolism, 1984: Dec., 769 Caliber, of firearm, 1983: June, 257–258 effect on tissue injury, 1983: June, 282–283

Calibration curves, in estimating probability of disease, 1984: Mar., 31-33

Cancer. See also under specific disease, as Breast, cancer.

CK₁ activity in, 1982: Sept., 493–506 collagen metabolites in, 1982: Sept., 519–542

detection, by mass screening, 1982: Sept., 627-638

by screening tests, 1982: Sept., 640 enzymatic activity in, 1982: Sept., 479-491

gastric, diagnosis of, rational approach to, 1984: Mar., 26–28

hemostatic abnormalities in, 1982: Sept., 599–625

laboratory measurements in, symposium on, 1982: Sept., 431-678

pancreatic, pancreas-specific antigen 1982: Sept., 567-578

test selection in, 1982: Dec., 876–878 polyamines in, 1982: Sept., 507–518 preclinical, detection of, 1982: Sept., 653–654

prostatic, test selection in, 1982: Dec., 692–695

screening tests, assessment of, 1982: Sept., 657-678

Cancer registry(ies), 1982: Sept., 633 Candles, ingestion of, 1984: Sept., 597 Carbon monoxide, levels, in fire victims, 1983: June, 298–299

poisoning, 1983: June, 400

Carboxyhemoglobin, levels, in fire victims, 1983: June, 299

Carboxypeptidase N, subcellular sites of, 1983: Dec., 581–584

Carcinoembryonic antigen, clearance, in primates, 1982: Sept., 459–467 in breast cancer, 1982: Sept., 550–555

in monitoring cancer, 1982: Sept., 550–553 in monitoring cancer, 1982: Sept., 663–664, 671–677

Carcinogen(s), safety standards for, 1983: Sept., 472

Carcinoid syndrome, neuroendocrine and chemical considerations, 1984: Dec., 803–815

Carcinoma, hepatocellular, due to environmental agents, 1984: Sept., 486–487

Cardiac metabolism, computer simulation of, 1982: Dec., 711

Cardiopulmonary bypass system, 1982: Mar., 65–69

Cardiovascular disorders, caused by plants, 1984: Sept., 607

Cardiovascular surgery, hemotherapy in, 1982: Mar., 65–85

Cardiovascular system, prostaglandins and, 1984: Dec., 791–792

Cartridge(s), firearm. See also Bullet(s). primers for, 1983: June, 258–259 rifle, characteristics of, 1983: June, 263–264

Catecholamines, and catecholamine catabolites, urinary, in diagnosis of pheochromocytoma, 1984: Dec., 706–713

Cathepsin G, in extracellular matrix degradation, 1983: Dec., 647–648Catheterization, in diagnosis of hypercorti-

Catheterization, in diagnosis of hypercortisolism, 1984: Dec., 698

Cathode ray tube (CRT) terminals, 1983: Mar., 173-174

Catnip, overdose, 1984: Sept., 611 Cavitation, in firearm wounds, 1983: June, 260, 277–281, 286–289

Cell, culture, in viral isolation, 1982: June, 384–386

destruction, antibody-mediated, 1982: Mar., 211-219

endothelial, in inflammatory response, 1983: Dec., 577–598

Central nervous system, plants affecting, 1984: Sept., 607

Central nervous system disorders, associated with prostaglandins, 1984: Dec., 791–792

Centrifugal force, relative, in recovery of mycobacteria, 1982: June, 312

Cervix, cancer, mass screening for, 1982: Sept., 628

screening for, 1982: Sept., 650 Chalk, ingestion of, 1984: Sept., 592

Charcoal, activated, for absorption of toxins, 1984: Sept., 621

Chediak-Higashi syndrome, neutrophil dysfunction and, 1983: Dec., 790-791

Chelation therapy, for acute iron poisoning in children, 1984: Sept., 580–581, 584–585

Chemical explosions, 1983: June, 311–313 Chemicals, nontoxic, ingestion, 1984: Sept., 587–602

toxic. See also specific agent. exposure in children, 1984: Sept., 469–473

in environment, behavior of, 1984: Sept., 451–459 interactions, 1984: Sept., 514–515 liver injury due to, 1984: Sept., 483–488

persistent, 1984: Sept., 510–514 Chemical testing, collection of specimens for, 1983: Sept., 524–529

Chemotactic defect(s), in neutrophil stimulation, 1983: Dec., 787-789

Chemotactic factor(s), in neutrophil stimulation, 1983: Dec., 782–783 in lung injury, 1983: Dec., 603–607 platelets and, 1983: Dec., 667-669

Chemotaxis, neutrophil, in burn injury, 1983: Dec., 804-806

Chest, radiograph, in lung infection, 1982: June, 289–290

Child(ren), acute iron poisoning in, 1984: Sept., 575–586

battered, 1983: June, 321-342 profile of, 1983: June, 326-327

chemical exposure in, 1984: Sept., 469-473

Child abuse, 1983: June, 321–342 radiographic evidence of, 1983: June, 322, 332–333 sudden infant death and, 1983: June,

338-342

Child abusors, profile of, 1983: June, 324–326

Chlamydia infection, respiratory, laboratory diagnosis of, 1982: June, 371–382

Cholestasis, clotting factor abnormalities in, 1984: June, 430

Chorionic gonadotropin, human, in germ cell tumors, 1982: Sept., 440-443

Chromatographic procedures, for hormone receptor measurement, 1984: Dec., 821, 822–823

Chromatography, gas-liquid, in anaerobic respiratory infection, 1982: June, 297 in mycobacterial infection, 1982: June, 317

in measurement of eicosanoids, 1983: Dec., 700

in toxicologic analysis, 1983: June, 373–374, 390–392

thin-layer, in mycobacterial infection, 1982: June, 316–317

Chromosome, analysis of, in diagnosis of endocrine diseases, 1984: Dec., 836–837
 HLA antigens and, 1982: Mar., 133
 linkage, blood group loci and, 1982: Mar., 137–141

Cigarettes, ingestion of, 1984: Sept., 594 Cirrhosis, abnormal coagulation factors in, 1984: June, 422–424, 432

bleeding in, treatment of, 1984: June, 430 euglobulin clot lysis in, 1984: June, 432 fibrinolytic activity in, 1984: June, 426–427

platelet function in, 1984: June, 420 Classification, of borderline disease, 1982: Dec., 744–745

of disease, by cluster analysis, 1982: Dec., 742–744

by pattern recognition, 1982: Dec., 720–730

Clerical tasks, computerized, in laboratory, 1983: Mar., 88–92, 98–100

Clinical laboratory. See also *Laboratory*. accreditation of, 1983: Sept., 448 compressed gases in, 1983: Sept., 470

Clinical laboratory (Continued) electrical safety in, 1983: Sept., 470 federal regulation of, 1983: Sept., 441–450 fire prevention and control in, 1983: Sept., 468–470

new tests in, planning and instituting, 1983: Sept., 413-422

organization of, 1984: Mar., 47–49 personnel management in, 1983: Sept.,

451–463 quality control for, 1983: Sept., 541–551 state licensing of, 1983: Sept., 448

state regulation of, 1983: Sept., 447 toxic and biological hazards in, 1983: Sept., 472

Clot(s), formation of, study of, methods of, 1984: June, 381

tests of, 1984: June, 295–297 stability of, tests of, 1984: June, 297–298 Clot lysis, euglobin, 1984: June, 297

Clot retraction, quantitative, 1984: June, 295

Clothing, fibers, as evidence, 1983: June, 364–365 postmortem examination of, 1983: June,

356–357 Clotting. See also Coagulation.

defects, after cardiopulmonary bypass, 1982: Mar., 75–78 of heparinized blood, 1982: Mar., 77

Clotting factors. See also specific factors. abnormalities in liver disease, 1984: June, 421–426

changes in level, in cardiovascular surgery, 1982: Mar., 73–75

vitamin K-dependent, 1984: June, 212–213

Clq binding assay, in diagnosis of occupational lung disease, 1984: Sept., 532 Clumping, See Agglutination.

Cluster analysis, in classification of disease, 1982: Dec., 742–744 in pattern recognition, 1982: Dec.,

in pattern recognition, 1982: Dec., 724–728

Coagulation, abnormal, in malignant disease, 1982: Sept., 604–609 biochemistry of, 1984: June, 207–220

disorders of, in liver disease, laboratory assessment of, 1984: June, 419-441 inhibitors of, natural, role in hemostasis,

1984: June, 245-284

normal, 1982: Sept., 600–603 pathways of. See *Coagulation pathways*. study of, immunoassays in, 1984: June, 345–361

in liver disease, 1984: June, 432–433 synthetic substrates for, 1984: June, 381–394

tissue factor in, 1984: June, 216, 223–224 vitamin K in, 1984: June, 210–214

Coagulation cascade, physiologic regulation of, 1984: June, 245

Coagulation complexes, vitamin K-dependent, 210, 1984: June, 210, 211

Coagulation factor(s), 1982: Sept., 602 in cancer patients, 1982: Sept., 605–609

Coagulation pathway(s), antithrombin III in, 1984: June, 246–247. See also Antithrombin III.

extrinsic, 1984: June, 207, **221–244** components of, 1984: June, 223–226 regulation of, 1984: June, 227–228

intrinsic, enzymes of, 1984: June, 207, 209

evaluation of, APTT in, 1984: June, 295 importance of, 1984: June, 221 reciprocal reactions between, 1984: June,

228 Coagulation tests, collection and handling of

specimens for, 1983: Sept., 531 Coding, of data, in laboratory information

system, 1983: Mar., 172–173 Cofactor(s), heparin, 1984: June, 246 Colchicine, for gout, 1983: Dec., 704

Colchicine, for gout, 1983: Dec., 704 Cold agglutinin syndrome, 1982: Mar., 207–208

Collagen metabolite(s), in malignant disease, 1982: Sept., 519–542

Collagenase, in extracellular matrix degradation, 1983: Dec., 647-650

College of American Pathologists Laboratory Accreditation Program, 1983: Sept., 448 Colloid(s), as fluid therapy, in critically ill, 1982: Mar., 35–63

Colon, cancer, screening tests for, consequences of diagnostic error, 1982: Dec., 782–784

Colorectal cancer, screening tests for, consequences of diagnostic error, 1982: Dec., 782–784

Colton system, 1982: Mar., 144

Combination testing, predictive value model in, 1982: Dec., 695–698 selection of, 1982: Dec., 871–890

by multivariate analysis, 1982: Dec., 735–750

Compatibility testing, pretransfusion, 1982: Mar., 169–179, 181–192

in autoimmune hemolytic anemia, 1982: Mar., 193–210

in cardiovascular surgery, 1982: Mar., 78_81

Complement, deficiency, in neutrophil dysfunction, 1983: Dec., 789

detection, by immunofluorescence, 1983: Dec., 757–758

effect on phagocytosis, 1982: Mar., 217–218

in chemotactic defects, 1983: Dec., 788-789 Complement activation, 1982: Mar., 216-217, 1983: Dec., 588-590

alternative pathway, in burn injury, 1983: Dec., 809–810 classic and alternative pathways of, 1983:

Dec., 578-579

in burn injury, 1983: Dec., 810-812 platelets and, 1983: Dec., 670-671

Complement assays, in diagnosis of occupational lung disease, 1984: Sept., 534–535

Complement component(s), effect on neutrophil chemotaxis, in burn injury, 1983: Dec., 805-806

effect on phagocytosis, in burn injury, 1983: Dec., 806–807

in inflammatory response, 1983: Dec., 578–583

in lung injury, 1983: Dec., 603-607

Complement system, biological activities of, 1983: Dec., 808–810

effect of burn injury on, 1983: Dec., 808–810

Complete blood count (CBC), collection and handling of specimens for, 1983: Sept., 530

Compressed gases, safe use of, 1983: Sept., 470

Computer information systems, applications, in combination testing, 1982: Dec., 737, 741–742

in pattern recognition, 1982: Dec., 717-734

in test selection, 1982: Dec., 703, 712 Darwinian, 1984: Mar., 18-19

hospital and laboratory linkage, 1983: Mar., 219-231

hospital-based, in monitoring health care, 1983: Mar., 179-204

implementation, in the laboratory, 1983: Mar., 233-250

in anatomic pathology, 1983: Mar., 133–147

in blood banking, 1983: Mar., 111–132 in clinical laboratory (symposium), 1983: Mar., 3–250

contracting, 1983: Mar., 19–34 controlled access to, 1983: Mar., 174–176

cost analysis of, 1983: Mar., 63–78 life cycle of, 1983: Mar., 6–7 pre-acquisition analysis, 1983: Mar., 3–18

reliability of, 1983: Mar., 165–177 request for proposal, 1983: Mar., 19–25 user-designed, 1983: Mar., 35–50 vendor selection, 1983: Mar., 19–34

in clinical microbiology, 1983: Mar., 101–110

in laboratory management, 1983: Mar., 149–163

in quality control studies, 1983: Sept., 548

microcomputer technology and, 1983: Mar., 51-62

networking of, 1983: Mar., 200 strengths and weaknesses, 1983: Mar.,

4–5, 80–82
Computer simulation, in models predicting cancer recurrence. 1982: Sept...

cancer recurrence, 1982: Sept., 675–677

of cardiac metabolism, 1982: Dec., 711 Conflagration. See Fire(s).

Congenital hemangiopericytomas, 1984: Mar., 148

Connective tissue disease, autoimmune, 1983: Dec., 754–757

"Consequences comparison" curve, for diagnostic test, defined, 1982: Dec., 780–781

Consultants, in system development, 1983: Mar., 8-9

Contact wounds, from firearms, 1983: June, 267-269

Contamination, of sputum specimens, 1982: June, 260–262

of respiratory specimens, in anaerobic infection, 291-292

Contraceptives, ingestion of, 1984: Sept., 595

Contract(s), for laboratory information system, 1983: Mar., 19-34, 246

Coombs' test. See Antiglobulin test. Coronary heart disease, test selection in, 1982: Dec., 792–793

Corpse, burned, identification of, 1983: June, 296–298

Correlation, of multiple laboratory tests, 1982: Dec., 884–887

Corticosteroid(s), pulmonary effects, following endotoxemia, 1983: Dec., 728-729

Corticotropin. See Adrenocorticotropic hormone.

Corticotropin-releasing hormone, measurement of, in hypercortisolism, 1984: Dec., 693

stimulation test, for hypercortisolism, 1984: Dec., 692–693

Cortisol, secretion of, regulation of, 1984: Dec., 684–686

serum, measurements of, in hypercortisolism, 1984: Dec., 696-698

Cost analysis,

in assessing diagnostic errors, 1982: Dec., 779–787

in assessing instrumentation, 1983: Sept., 437

in assessing laboratory information system, 1983: Mar., 63-78

in test evaluation, 1982: Dec., 821-833 of laboratory, 1983: Sept., 425 of laboratory tests, 1983: Sept., 413

Cost analysis (Continued)

of laboratory utilization, 1983: Mar., 189_193

Cost-benefit model, in therapeutic decisionmaking. See Threshold approach.

Coumarin therapy, for protein C disorders, 1984: June, 271

"Crash" recovery, in laboratory information system, 1983: Mar., 248

Crayons, ingestion of, 1984: Sept., 592 Creatine kinase, in human tissue, 1982:

Sept., 495

variants, in cancer, 1982: Sept., 500-502 Creatine kinase isoenzyme, in malignant disease, 493-506

Crib death. See Sudden infant death. Crossmatch, cost effectiveness of, 1982: Mar., 191

in emergency cardiovascular surgery, 1982: Mar., 78-81

preoperative, 1982: Mar., 169-179 pretransfusion, evaluation of, 1982: Mar.,

pretransplantation, 1983: Dec., 765-767 Cryoprecipitate, transfusion, 1982: Mar., 14-17

Crystalline compound(s), in inflammatory response, prostaglandins and, 1983: Dec., 703-704

Crystalloid(s), as fluid therapy, in critically ill, 1982: Mar., 35-63

Culture, anaerobic, collection and handling of specimens for, 1983: Sept., 534 bacterial, of sputum specimen, 1982:

June, 262 blood, preanalytic factors in, 1983: Sept.,

fungal, of respiratory specimens, 1982: June, 266

in recovery of Chlamydia, 1982: June, 377 media, in Legionella infection, 1982: June, 362-363

of Pneumocustis carinii, 1982: June, 404 of respiratory specimens, in fungal infec-

tion, 1982: June, 325-328 stool, preanalytic factors in, 1983: Sept., 534

tissue, in viral isolation, 1982: June, 384-386

urine, preanalytic factors in, 1983: Sept., 532

Current, electrical. See Electrical current. Cushing's syndrome, 1984: Dec., 683-702

Cyanide intoxication, caused by Laetrile, 1984: Sept., 606

Cyclic AMP, concentrations, following endotoxemia, 1983: Dec., 732

> in neutrophil stimulation, 1983: Dec., 785-786

urinary, measurement of, in assessment of mineral metabolism, 1984: Dec., 770

Cyclic GMP, concentrations, following endotoxemia, 1983: Dec., 732

in neutrophil stimulation, 1983: Dec., 785-786

Cyclic nucleotides. See Cyclic AMP; Cyclic GMP.

Cyclooxygenase, inhibition of, 1983: Dec., 725-726

Cyclooxygenase pathway, of arachidonate metabolism, 1983: Dec., 679-681

Cyclosporine, in organ transplantation, 1983: Dec., 770

Cytapheresis. See specific procedure, as Leukapheresis.

Cytogenetic techniques, for diagnosis of endocrine diseases, 1984: Dec., 835-844

Cytology, aspiration, limitations and value of, 1984: Mar., 89-98

Cytolysis, antibody-mediated, 1982: Mar., 211-219

Danish Breast Cancer Group (DBCG) study. of tumor markers, 1982: Sept., 659-677

Darwinian computer, 1984: Mar., 18-19 Data, analysis. See specific technique, as Cluster analysis.

bases, in automated blood bank, 1983: Mar., 115-117

in clinical laboratory, 1983: Mar., 222-223

in hospital information system, 1983: Mar., 179-204

in laboratory information system, 1983: Mar., 240

management system, 1983: Mar., 42 of laboratory test results, 1982: Dec., 815-816

display, in pattern recognition, 1982: Dec., 723-724

elements, in laboratory information system, 1983: Mar., 220-229

entry, in automated blood bank, 1983: Mar., 118-122

in microbiologic computer system, 1983: Mar., 103, 108

reliability, 1983: Mar., 173

gathering, in evaluating the patient exposed to a hazardous substance, 1984: Sept, 500-502

management, in automated blood bank, 1983: Mar., 114-126

instrumentation needs and, 1983; Sept., 430-431

processing, automated. See Computer information systems.

DDT, human exposure to, 1984: Sept., 510-514

Death, alcoholic, investigation of, 1983: June, 392-395

autopsy in. See Autopsy.

drug-related, investigation of, 1983: June, 368-370, 377-379

from electrocution, 1983: June, 343–353 from explosion, 1983: June, 309–319

from fire, 1983: June, 295–307 from firearm wounds, 1983: June, 257–271, 273–294

of battered child, investigation of, 1983: June, 327–341

product-related, pathologist's role, 1984: Sept., 629-636

Debugging, of laboratory information system, 1983: Mar., 241–242

Decision analysis, 1984: Mar., 33–37 in test evaluation, 1982: Dec., 764–775, 821–833

Decision-making, autopsy information and, 1984: Mar., 176

clinical, process of, 1982: Dec., 701–702 role of new laboratory test in, 1982: Dec., 751–777

in test selection, symposium on, 1982: Dec., 685–901

of expert clinicians, 1982: Dec., 814–815 rational, 1984: Mar., 25–26

thresholds for, 1984: Mar., 32–38 Deep-compartment probes, for toxic chemicals, 1984: Sept., 502, 505–506

Deferoxamine, for chelation therapy in acute iron poisoning in children, 1984: Sept., 580–581, 584–585

Dehydration test, for antidiuretic hormone function, 1984: Dec., 737-739

Dermatitis, due to toxic plant exposure, 1984: Sept., 604

Dermatologic. See Skin.

Design defect cases, 1983: June, 402–404 Detergents, ingestion of, 1984: Sept., 593 Detonating explosions, 1983: June, 313

Dexamethasone suppression tests, for hypercortisolism, 1984: Dec., 687-691

Dextran-coated charcoal assay, for hormone receptor measurement, 1984: Dec., 820-821

Diabetes mellitus, antibody markers of, 1983: Dec., 752

diagnosis of, 1984: 753-754

gestational, diagnosis of, 1984: Dec., 754–755

laboratory evaluation, 1984: Dec., 745-761 management of, monitoring, 1984: Dec.,

755–756 test selection in. 1982: Dec., 796–797

test selection in, 1982: Dec., 796–797 Diagnosis, clinical and pathologic, discrepancies between, 1984: Mar., 175

computer-assisted, in anatomic pathology, 1983: Mar., 143

incorrect and missed, significance of, 1984: Mar., 174

Diagnosis retrieval systems, computerized, 1983: Mar., 134–139

Diagnostic accuracy, early studies of, 1984: Mar., 171-172

Diagnostic process, algorithms in, 1984: Mar., 7

computer methods in, 1984: Mar., 9 mathematical methods in, 1984: Mar., 7 neurophysiologic and neuroanatomic bases of, 1984: Mar., 14–19

pathologist and, 1984: Mar., 3–23 probabilistic methods in, 1984: Mar., 8 psychological aspects of, 1984: Mar., 11–14

stages of, 1984: Mar., 4-10

Diagnostic tests. See Laboratory test(ing). Dialysis encephalopathy, aluminum and, 1984: Sept., 492–493

Diego system, 1982: Mar., 144

Dilution susceptibility testing, 1984: Mar., 105

Diphenhydramine, pulmonary effects, following endotoxemia, 1983: Dec., 730–731

Disc diffusion susceptibility testing, 1984: Mar., 105

Discounting, of cash flows, 45-46; 1983: Mar., 75

Discriminant function analysis, in test selection, 1982: Dec., 729–730, 735–750

of markers, in monitoring cancer, 1982: Sept., 667–671

Disease, borderline, classification of, 1982: Dec., 744–745 changing definition of, 1984: Mar., 3

classification of, by cluster analysis, 1982: Dec., 742–744

by pattern recognition, 1982: Dec., 720–730

incidence of, autopsy information for deriving, 1984: Mar., 171

monitoring of, serial testing in, 1982: Dec., 842–847

timing of laboratory tests in, 1982: Dec., 851-870

prevalence, predictive value, and 1982: Dec., 685

probability of, autopsy in determining, 1984: Mar., 171 estimating, 1984: Mar., 28–32

Display techniques, for data, in pattern recognition, 1982: Dec., 723-724

Disseminated intravascular coagulation, decreased antithrombin III survival due to, 1984: June, 262

incompatible transfusion and, 1982: Mar., 228–229

in liver disease, 1984: June, 428-429 laboratory findings in, 1984: June, 299

Diurnal rhythm, in regulation of cortisol secretion, 1984: Dec., 685 Dose-response relationship, in toxicology, 1984: Sept., 507–519

"Down time," of hardware, in laboratory information system, 1983: Mar., 167 Drug(s). See also under specific drugs.

affecting prostaglandin synthesis and action, 1984: Dec., 788–790

poisoning by, investigation of, 1983: June, 367–385

resistance, in tuberculosis, 1982: June, 313

therapy, in anaerobic respiratory infection, 1982: June, 300–301 in anaphylaxis, 1983: Dec., 627

in inflammatory disease, 1983: Dec., 685–689

in tuberculosis, 1982: June, 315–316 toxic concentrations of, 1983: June, 381–382

Duffy system, 1982: Mar., 144 "Duty to warn" concept, 1984: Sept., 634–635

Dysfibrinogenemia(s), 1984: June, 395–418 acquired, 1984: June, 402–405 congenital, 1984: June, 405–411 in chronic liver disease, 1984: June, 422–424

laboratory evaluation of, 1984: June, 400–402

thrombotic disorders in families with, 1984: June, 408

Ectopic hormones, as tumor markers, 1984: Dec., 775–786

Edelman's group selection theory, 1984: Mar., 14-17

Edema, pulmonary, fluid therapy in, 1982: Mar., 39-49

following endotoxemia, 1983: Dec., 723 Eicosanoid(s). See specific substance, as

Prostaglandin(s); Thromboxane(s). Elastase, in extracellular matrix degradation, 1983: Dec., 647–651

in inflammatory response, 1983: Dec., 583–585

in neutrophil-mediated lung injury, 1983: Dec., 611

Electrical burns. See Burn(s), electrical. Electrical current, 1983: June, 347–352

Electrical equipment, faulty, examination of, 1983: June, 349–352

Electrical explosions, 1983: June, 310–311 Electrical injury, 1983: June, 310–311, 343–353

blood in, 1983: June, 346 from lightning, 1983: June, 352–353

Electrical safety, 1983: Sept., 470 Electricity, atmospheric. See Lightning. physics of, 1983: June, 343-344 types of, 1983: June, 347-353

Electrocution, 1983: June, 343–353 by defective product, 1983: June, 349–352, 403

deaths by, pathologist's role, 1984: Sept., 633

Electroimmunoassay, Laurell rocket, 1984: June, 347

Electrolyte analysis, collection of specimens for, 1983: Sept., 524

Electronmicroscopy, 1984: Mar., 123–164. See also specific lesions.

Electrophoresis, of glycoproteins, 1982: Sept., 472–474

Embolism, pulmonary, test selection in, 1982: Dec., 792

Embryonal rhabdomyosarcoma, 1984: Mar., 158

Emesis, induction of, for poisoning, 1984: Sept., 620

Emphysema, pulmonary, pathology of, 1984: Sept., 539–559

Encryption, of data, in laboratory information system, 1983: Mar., 172–173
Endocrine disease, autoimmune, 1983:

Endocrine disease, autoimmune, 1983: Dec., 750–753

diagnosis of, cytogenetic techniques for, 1984: Dec., 835–844

Endocrine function, laboratory evaluation of, 1982: Dec., 796–797, 803–819 Endocrine studies, collection and handling

of specimens for, 1983: Sept., 528 Endocrine system, mass effects of pituitary

tumors on, 1984: Dec., 644–647 Endocrinology, symposium on, 1984: Dec., 641–844

Endothelial cell(s), in regulation of coagulation cascade, 1984: June, 245

in thrombin-antithrombin III reactions, 1984: June, 252–254

interaction with thrombin, 1984: June, 273

Endothelium, complement inactivation and, 1983: Dec., 579–581

in inflammatory response, 1983: Dec., 577–598

injury to, following endotoxemia, 1983: Dec., 723

granulocytes and, 1983: Dec., 737–739 neutrophil adherence to, in lung injury, 1983: Dec., 603–605

permeability of, by neutrophils, 1983: Dec, 607–612

response to injury, 1983: Dec., 586–592 Endotoxemia, lung injury and, 1983: Dec., 719–744

Endotoxin, effect on neutrophils, in lung injury, 1983: Dec., 605

immunosuppressive effects, in burn injury, 1983: Dec., 803

Enteropathy, protein-losing, decreased antithrombin III survival with, 1984:
June, 263

Entrance wounds, firearm, 1983: June, 264–270

Environment, physical, for hardware, 1983: Mar., 169, 238–240

Enzyme(s). See also specific enzymes, as Carboxypeptidase; Angiotensin converting enzyme.

activity, in cancer, 1982: Sept., 479-491 analysis, 1983: Sept., 526-528

for antithrombin III assays, 1984: June, 264

in blood clotting, 1984: June, 207 in breast cancer, 1982: Sept., 547 in malignant disease, 1982: Sept.,

493-506 pancreatic, in cancer, 1982: Sept., 482-483

Enzyme-linked immunosorbent assay (ELISA), of pancreas-specific antigen, 1982: Sept., 572–574

Enzyme markers, of myocardial infarction, 1982: Dec., 707–708

Enzyme testing, predictive value model in, 1982: Dec., 687, 696–698

Ergonomic design, of laboratory information system, 1983: Mar., 173-174

Error, diagnostic, in laboratory testing, 1982: Dec., 779–787

Erythrapheresis, therapeutic, 1982: Mar., 101–102

101-102
Erythroblastosis fetalis. See Hemolytic disease.

Erythrocyte(s), agglutination, 1982: Mar., 155–167

destruction, antibody-mediated, 1982: Mar., 211–219

transfusion of, in critically ill, 1982: Mar., 52

washed, 1982: Mar., 224, 245–246 Erythrocyte antigens, 1982: Mar., 144–146 Rh system and, in hemolytic disease of newborn, 1982: Mar., 107–122

typing, in autoimmune hemolytic anemia, 1982: Mar., 198–199

Erythrocyte membrane, 1982: Mar., 155–159

agglutination and, 1982: Mar., 161–162 Erythroid disorder(s), test selection in, 1982: Dec., 708

Estrogen receptors, in breast cancer, measurement of, 1984: Dec., 825–828

Ethanol. See Alcohol.

Ethyl alcohol. See Alcohol, ethyl. Eucalyptus oil, overdose, 1984: Sept., 610 Euglobin clot lysis, 1984: June, 297

Evaporation, of toxic compounds in the environment, 1984: Sept., 456

Evidence, blood samples as, 1983: June, 360–362

in explosions and bombings, 1983: June, 305, 317-318

in fires, 1983: June, 303-304

in product liability deaths, 1983: June, 403

radiographic, in child abuse, 1983: June, 322, 332–333

in firearm wounds, 1983: June, 269–270 toxicologic, 1983: June, 375–383, 392–395 trace, 1983: June, 355–365

Ewing's sarcoma, electronmicroscopic diagnosis of, 1984: Mar., 151, 156–157, 160, 161

Expert witness, in product liability case, 1983: June, 401–402

Explosion(s). See also Bombing(s). chemical, 1983: June, 311–313 electrical, 1983: June, 310–311 gas, 1983: June, 312–313 injuries from, 1983: June, 304–305,

309–319 mechanical, 1983: June, 309–310 physics of, 1983: June, 309–313

Explosive(s), classification of, 1983: June, 311–313

Eye, aspiration cytology of, 1984: Mar., 90 exposure of to toxins, treatment, 1984: Sept., 618

Factor(s), coagulation. See Coagulation factor(s) or under specific factor, as Fibrinogen.

Factor V, 1984: June, 213-214 in assessment of chronic liver disease, 1984: June, 423, 432-433

Factor VII, activation of, 1984: June, 225–226

assays of, 1984: June, 229–230 clinical abnormalities of, 1984: June, 234–239

deficiency of, acquired, 1984: June, 238-239

hereditary, 1984: June, 234–238 thrombotic complications of, 1984: June, 235, 236

treatment of, 1984: June, 235, 238 human, monoclonal antibody to, 1984: June, 233

immunoassay of, 1984: June, 354 in blood coagulation, 1984: June, 224–226 increased activity of, 1984: June, 239 in evaluation of cirrhosis, 1984: June, 424, 432, 433

laboratory evaluation of, 1984: June, 229–230

synthesis of, 1984: June, 226 variants of, 1984: June, 237 Factor VIIa, quantitation of, 1984: June, 233 Factor VII antigen, radioimmunoassay of, 1984: June, 233

Factor VII:C, activation of, 1984: June, 216 assays for, amidolytic, 1984: June, 230-231

Factor VIII, assays of, synthetic substrate for, 1984: June, 389–390 immunoassays of, 1984: June, 354–355

Factor VIII, in cancer patients, 1982: Sept., 606–607

June, 304

Factor VIII antigen, ABC-ELISA in evaluation of, 1984: June, 349, 351

Factor VIII:C, activity of, in platelet-type von Willebrand's disease, 1984: June, 321

in assessment of liver disease, 1984: June, 423, 432–433

Factor IX, activation of, radiometric assays of, 1984: June, 231–233

Factor IX antigen assays, 1984: June, 355 Factor X, activation of, radiometric assays for, 1984: June, 231–233

immunoassays of, 1984: June, 355 Factor XI, immunoassay of, 1984: June, 355 Factor XII, immunoassay of, 1984: June, 356 Factor XIII, immunoassay of, 1984: June,

356 in assessment of liver disease, 1984: June, 423

Failure to thrive, evaluation of, 1983: June, 337–338

False negatives, consequences of, in laboratory diagnosis, 1982: Dec., 779-787

False positives, consequences of, in laboratory diagnosis, 1982: Dec., 779–787
 False-positive rate, defined, 1982: Dec.,

689-690

Fc receptors, 1983: Dec., 579–581 Feasibility study, for laboratory information system, 1983: Mar., 63–78

Federal government, in regulation of clinical laboratory, 1983: Sept., 441–447

Ferritin, in breast cancer, 1982: Sept., 547 Fetal fibrinogen, 1984: June, 399

Fetal-maternal hemorrhage, dose of Rh immune globulin and, 1982: Mar., 115–117

Fibers, as evidence, 1983: June, 364–365
Fibrillation, ventricular, in electrical injury, 1983: June, 347, 349, 352

Fibrin, aggregation defects of, asymptomatic, 1984: June, 407 formation of, functional evaluation of,

1984: June, 400–401 physiology of, 1984: June, 395–399

Fibrinogen, abnormalities of, acquired, 1984: June, 402–405

congenital, 1984: June, 405–411 inherited qualitative, 1984: June, 395–418

evaluation of, 1984: June, 400–402 thrombotic disorders with, 1984: June, 408

fetal, 1984: June, 399 functional sites on, 1984: June, 397 in cancer patients, 1982: Sept., 605–606 physiology of, 1984: June, 395–399 platelet, 1984: June, 410

radioimmunoassay of, 1984: June, 353 Fibrinogen Tokyo II, 1984: June, 407 Fibrinopentide A. assays of 1984: June

Fibrinopeptide A, assays of, 1984: June, 353, 367–369

blood collection and storage for, 1984: June, 368–369

in control of anticoagulant therapy, 1984: June, 375–377

in diagnosis of deep venous thrombosis and pulmonary embolism, 1984: June, 363–380

specificity of, 1984: June, 368 formation and plasma clearance of, 1984: June, 365–367

plasma concentrations of, normal, 1984: June, 370

slow release of, 1984: June, 405–406 Fibrinolysis, abnormal, in malignant disease, 1982: Sept., 609–616 normal, 1982: Sept., 603–604

Fibronectin, effect on phagocytosis, in burn injury, 1983: Dec., 806–807

Fibrous mesothelioma, electronmicroscopic diagnosis of, 1984: Mar., 130–137 Fifth-year training controversy, 1984: Mar.,

185-200
Fine needle aspiration biopsy, 1984: Mar., 89-98. See also Aspiration cytology.

Fingernail(s), as evidence, 1983: June, 358, 363 Fingerprinting, of unidentified corpse, 1983:

June, 297
Fire(s), death from, investigation of, 1983:
June, 295–307

prevention and control, in laboratory, 1983: Sept., 468–470

Firearm(s). See Rifled weapon(s). Firearm wounds, 1983: June, 257–271, 273–294

bullet track in, 1983: June, 260, 277–281, 286–289

contact, 1983: June, 267–269 distant range, 1983: June, 264–266 intermediate range, 1983: June, 266–267 of head, 1983: June, 265–268, 287–288 of liver, 1983: June, 285–287 of muscle, 1983: June, 283–285

Fitzgerald factor, immunoassay of, 1984: June, 355 Fletcher factor, immunoassay of, 1984: June, 356

Flora, indigenous, in anaerobic pleuropulmonary infection, 1982: June, 286–287

Fluid(s), body, alcohol levels in, 1983: June, 386–395

drug levels in, 1983: June, 369–370 Fluid therapy, algorithms, in critically ill, 1982: Mar., 53–60

1982: Mar., 53-60 in critically ill, 1982: Mar., 35-63

Fluorescent antinuclear antibody test, in SLE, 1982: Dec., 881–884

Forensic pathology, symposium on, 1983: June, 257-405

Forensic toxicology, 1983: June, 385–386 Formatting, of information, in computerized

laboratory, 1983: Mar., 79–100. See also Report format(s).

FORTRAN, 1983: Mar., 6-7. See also Programming languages.

Fracture(s), in battered child, 1983: June, 322–323, 332–333

in fire victims, 1983: June, 302 in firearm wounds, 1983: June, 282-283

Free thyroxine assays, controversies in, 1984: Dec., 671–678

Free thyroxine index, controversies in, 1984: Dec., 673–674

Fungus(i), opportunistic pulmonary infection, laboratory diagnosis of, 1982: June, 407–413

respiratory infection, laboratory diagnosis of, 1982: June, 321–342 susceptibility testing of, 1984: Mar., 115

Galactosyltransferase, as tumor marker, 1982: Sept., 475

Galactosyltransferase isoenzyme II, in pancreatic cancer, 1982: Dec., 876–878

Gamma-glutamyltranspeptidase, in hepatic cancer, 1982: Sept., 483–484

Gas(es), blood, collection and handling of specimens for, 1983: Sept., 525 compressed, safe use of, 1983: Sept., 470 explosive limits of, 1983: June, 312

Gas explosions, 1983: June, 312–313 Gas-liquid chromatography, in anaerobic respiratory infection, 1982: June, 297

respiratory infection, 1982: June, 297 in mycobacterial infection, 1982: June, 317

Gastric cancer, diagnosis of, rational approach to, 1984: Mar., 26–28
 Gastric lavage, for poisoning, 1984: Sept.,

Gastroenteritis, plant ingestion presenting as, 1984: Sept., 605

Gastrointestinal bleeding, in liver disease, surgery for, 1984: June, 430 in von Willebrand's disease, 1984: June, 310–311

Gastrointestinal system, effect of carcinoid syndrome of, 1984: Dec., 809

prostaglandins and, 1984: Dec., 793 Gastrointestinal tract, cancer, CK₁ activity in, 1982: Sept., 497

decontamination of, guidelines for, 1984: Sept., 591-592

in acute iron poisoning in children, 1984: Sept., 583–584

in children, as route of entry to xenobiotics, 1984: Sept., 470

Gelatinase, in extracellular tissue degradation, 1983: Dec., 647-648

Gene mapping, of blood group loci, 1982: Mar., 137-141

Genetic factors, in autoimmune disorders, 1983: Dec., 746 in chronic granulomatous disease, 1983:

Dec., 792 Germ cell tumor(s), extragonadal, markers for, 1982: Sept., 454–456 infantile, 1982: Sept., 447

markers for, 1982: Sept., 431-458 Giemsa stain, in *Pneumocystis* infection,

1982: June, 399 Glass, as evidence, 1983: June, 363–364

Glucocorticoids, in prostaglandin inhibition, 1984: Dec., 789
Glucocorticosteroid(s), affect on inflamma-

tory response, 1983: Dec., 708
Glucose. See also under disorders such as

Hypoglycemia determinations, 1983: Sept., 525 measurement of, in diabetes and hypoglycemia, 1984: Dec., 749–750

Glucose tolerance, impaired, diagnosis of, 1984: Dec., 753-754

Glucose tolerance testing, 1984: Dec., 752

Glycoprotein(s), as tumor markers, 1982: Sept., 469-477

Glycosyltransferase(s), in breast cancer, 1982: Sept., 547

in cancer, 1982: Sept., 485–487

Gonad(s), germ cell tumors of, markers for, 1982: Sept., 431–458

Gonadal function, disorders of, 1984: Dec., 717-728

Gonadotropin-resistant ovary syndrome, 1984: Dec., 722–723

Gonadotropins, ectopically produced, 1984: Dec., 780–781

human chorionic, in germ cell tumors, 1982: Sept., 440-443

hypersecretion of by pituitary adenomas, 1984: Dec., 652

mass effects of pituitary tumors on, 1984: Dec., 647 Graft, rejection, mechanisms of, 1983: Dec., 764-765

Graft-versus-host disease, blood transfusion and, 1982: Mar., 130

in marrow transplantation, 1982: Mar., 129

Gram's stain, in anaerobic respiratory infection, 1982: June, 296–297

in evaluation of respiratory specimens, 1982: June, 265

in Legionella infection, 1982: June, 356-257

Gram-Weigert stain, in *Pneumocystis* infection, 1982: June, 401–403

Granulocyte(s), in endotoxin-induced lung injury, 1983: Dec., 732–739

Granulomatous disease, chronic, neutrophil dysfunction and, 1983: Dec., 792

Graphic output, in laboratory information system, 1983: Mar., 155

Graves' disease, 1983: Dec., 750

Gross cystic disease fluid protein (GCDFP-15), in breast cancer, 1982 Sept., 555-558

Group selection theory, 1984: Mar., 14–17 Growth hormone, hypersecretion of by pituitary adenomas, 1984: Dec., 649–650 mass effects of pituitary tumors on, 1984: Dec., 645

Gun. See Rifled weapon(s).

Gunshot wounds. See Firearm wounds.

Hageman factor, 1984: June, 207 Hair, analysis of, 1983: June, 370 in fire deaths, 1983: June, 298 as evidence, 1983: June, 357, 363

as evidence, 1993; June, 357, 363 Hardware, microcomputer, 1983; Mar., 53 reliability, in laboratory information system, 1983; Mar., 166–169

security, in laboratory information system, 1983: Mar., 169–170
selection, in user-designed system, 1983:

selection, in user-designed system, 1983: Mar., 45-46

Hardware configuration, in laboratory information system, 1983: Mar., 238

Hardware installation, in laboratory information system, 1983: Mar., 238–240

Hardware maintenance, in laboratory information system, 1983: Mar., 235 contract for, 1983: Mar., 32–33

Hashimoto's disease, 1983: Dec., 750 Hashimoto's thyroiditis, diagnosis of, 1984:

Mar., 92 Hazardous wastes, disposal of, 1983: Sept., 477–480

Head and neck, hemangiopericytomas in, 1984: Mar., 145, 148 Head wounds, from firearms, 1983: June, 265–268, 287–288

in battered child, 1983: June, 328–336 Health care, computerized evaluation of, 1983: Mar., 179–204

Health hazards, resources available for patient evaluation, 1984: Sept., 499-506

Health Insurance Plan (HIP) study, for breast cancer, 1982: Sept., 627–638

Heart. See also Cardiac.

attack. See Myocardial infarction. disease, coronary, test selection in, 1982: Dec., 792–793

in carcinoid syndrome, 1984: Dec., 809 transplantation, 1983: Dec., 773–774 ventricular fibrilation, in electrical injury,

1983: June, 347, 349, 352 Hemangiopericytoma, electronmicroscopic

diagnosis of, 1984: Mar., 137, 142–148 Hemapheresis, therapeutic, 1982: Mar., 87–106. See also specific type of ther-

apy, as *Leukapheresis*. Hematoplogic malignancy(ies), CK₁ activity

in, 1982: Sept., 499–500 Hematologic testing, preanalytic factors in, 1983: Sept., 529–531

Hematology, prostaglandins and, 1984: Dec., 794

Hematology laboratory, safety standards for, 1983: Sept., 477

Hematoma, in fire victims, 1983: June, 301–303

subdural, in battered child, 1983: June, 334

Hematopoietic function, effect of lead intoxication on, 1984: Sept., 490 effect of toxic plants on, 1984: Sept., 606

Hemochromatosis, HLA-A antigen and, 1982: Mar., 132

Hemocytoblast. See Stem cell.

Hemoglobin, glycated, measurement of, in diabetes and hypoglycemia, 1984: Dec., 750-751

Hemoglobinuria, paroxysmal cold, 1982: Mar., 208–209

Hemolysis, antibodies and, 1982: Mar., 211-219

Hemolytic disease, of newborn, 1982: Mar., 107–122

multiple laboratory testing in, 1982: Dec., 696-698

Hemolytic transfusion reactions, 1982: Mar., 79, 221-231

Hemophilia, acquired immunodeficiency syndrome (AIDS) with, 1984: June, 333-344

immune abnormalities and laboratory findings in, 1984: June, 338–340

Hemophilus influenzae, susceptibility testing of, 1984: Mar., 110 Hemorrhage, antibiotic-induced, 1984: June,

in fire victims, 1983: June, 301-303 maternal-fetal, dose of Rh immune globulin and, 1982: Mar., 115-117 subdural, in battered child, 1983: June,

334-335

Hemorrhagic diathesis(es), laboratory evaluation of, 1984: June, 285-301

Hemosiderin. See Iron.

Hemostasis, abnormal, in malignant disease, 1982: Sept., 599-625

after vascular injury, 1984: June, 207-209 antithrombin III in, 1984: June, 246-266 complex abnormalities of, evaluation of, 1984: June, 298-299

contribution of, endothelial cells to, 1984: Iune, 274

determinants of, 1984: June, 285

disorders of. See specific disorders, as von Willebrand's disease.

laboratory evaluation of, immunoassays in, 1984: June, 344-361

natural coagulation inhibitors in, 1984: June, 245-284

protein C in, 1984: June, 266-274 role of extrinsic coagulation system in, 1984: June, 226-229

role of von Willebrand factor in, 1984: June, 305-308

tests of, 1984: June, 293. See also specific tests, as Bleeding time.

Hemotherapy, symposium on, 1982: Mar., 3-252. See also specific procedures, as Leukapheresis.

in acute hepatic necrosis, 1984: June,

inhibitory properties of, 1984: June, 246 interaction with antithrombin III, 1984: June, 247, 249, 251

Heparin cofactor, 1984: June, 246 Heparin cofactor II, 1984: June, 247

Heparin therapy, decreased plasma antithrombin III activity with, 1984: June,

during pregnancy, 1984: June, 260 Hepatic. See also Liver.

injury, due to environmental agents, 1984: Sept. 483-488

Hepatitis, acute, clotting factors in, vitamin K-dependent, 1984: June, 425

viral, platelet function in, 1984: June, 421 transfusion-transmitted, 1982: Mar., 233-252

Hepatitis A virus, 1982: Mar., 240-241 Hepatitis B immune globulin (HBIG), 1982: Mar., 247

Hepatitis B virus, 1982: Mar., 241-242 Heptitis non-A, non-B, 1982: Mar., 242-243 Hepatoma, clotting factor abnormalities in,

1984: June, 430

Herbs, overdose, 1984: Sept., 608-610 Hermaphroditism, cytogenetic evaluation. 1984: Dec., 841

HETE. See Hydroxyeicosatetraenoic acid. High-performance liquid chromatography, in measurement of estrogen receptors in breast cancer, 1984: Dec., 825-826

Histamine, hyperresponsiveness to, following endotoxemia, 1983: Dec., 720-722 in anaphylaxis, 1983: Dec., 619-620 in endotoxin-induced lung injury, 1983:

Dec., 729-730

Histocompatibility complex. See IILA. Histocompatibility testing, mixed lymphocyte culture and, 1982: Mar., 128

Histiocytoma, malignant fibrous, electromicroscopic diagnosis of, 1984: Mar., 123 - 130

Hit-and-run accident, collection of evidence in, 1983: June, 357, 364

HLA antigens, disease associations and, 1982: Mar., 130-132; 1983: Dec., 747-748

HLA loci, 1982: Mar., 123-125 HLA typing, clinical applications of, 1982: Mar., 123-135

pretransplantation, 1983: Dec., 776

Hodgkin's disease, classification of, 1982: Sept., 589

Homeostatic autoregressive model, in monitoring cancer, 1982: Sept., 672-77 Homicide, attempted concealment of, 1983:

Hormonal disorders, of neonate, 1981: June, 399-418

Hormone(s). See also specific types. ectopic, as tumor markers, 1984: Dec., 775-786

excess secretion by pituitary adenomas, 1984: Dec., 647-653 urinary, 1983: Sept., 529

Hormone receptor measurements, 1984: Dec., 817-833

Hospital, accreditation of, Joint Commission on, 1983: Sept., 447

Hospital information system, linkage with laboratory information system, 1983: Mar., 219-231 medical applications, 1983: Mar., 179-204

Host defense(s), effect of burn injury on, 1983: Dec., 801-802

HPETE. See Hydroperoxyeicosatetraenoic acid.

Hybridoma technology, in organ transplantation. 1983: Dec., 777

Hydroperoxyeicosatetraenoic acid, chemotactic activity of, 1983: Dec., 669 in anaphylaxis, 1983: Dec., 621-625 in neutrophil stimulation, 1983: Dec., 786-787

production of, 1983: Dec., 681

Hydroxyeicosatetraenoic acid, chemotactic activity of, 1983: Dec., 669

in anaphylaxis, 1983: Dec., 621-625 in endotoxin-induced lung injury, 1983: Dec., 728

in neutrophil stimulation, 1983: Dec., 786-787

macrophage-derived, in inflammatory response, 1983: Dec., 684–688

production of, 1983: Dec., 680–682 5-Hydroxyindoleacetic acid, in carcinoid

syndrome, 1984: Dec., 805–810 Hydroxyproline, in assessment of bone metabolism, 1984: Dec., 768

in malignant disease, 1982: Sept., 519-542

5-Hydroxytryptamine, in carcinoid syndrome, 1984: Dec., 804–805, 810

Hyperalimentation, decreased antithrombin III synthesis with, 1984: June, 262

Hypercalcemia, effect of ectopic parathormone on, in, 1984: Dec., 779 laboratory evaluation of, 1982: Dec.,

809-812

Hypercortisolism, 1984: Dec., 683–702 Hyperglycemia, laboratory tests for, 1984:

Dec., 745–761
Hyperinsulinism. See *Hypoglycemia*.
Hyperleukocytosis, leukapheresis and, 1982:

Mar., 98–99

Hyperparathyroidism, test selection in,

1982: Dec., 809-812 Hypersensitivity reaction(s). See Anaphy-

laxis.
Hypertension, consequences of diagnostic

error, 1982: Dec., 784–785 in pheochromocytoma, 1984: Dec., 705–706

test selection in, 1982: Dec., 793–796 Hyperthyroidism, test selection in, 1982: Dec., 797–798

thyroid function tests in, 1984: Dec., 661-663

thyrotropin assays and, 1984: Dec., 680

Hypertonic saline infusion, in assessment of antidiuretic hormone function, 1984: Dec., 740–741

Hyperviscosity syndrome, plasmapheresis and, 1982: Mar., 95-96

Hypoglycemia, diagnosis of, 1984: Dec., 756–758

laboratory tests for, 1984: Dec., 745–761 Hypogonadism, hypergonadotropic, 1984: Dec., 721–722

male, 1984: Dec., 719-720

Hypothermia, therapeutic, in cardiovascular surgery, 1982: Mar., 82-84

Icterus. See Jaundice.

Icterus neonatorum. See Hemolytic disease of newborn.

IgE antibody, immunoassays for, in occupational lung disease, 1984: Sept., 526–527

Imidazole, affect on inflammatory response, 1983: Dec., 707

Immune adherence, in cell destruction, 1982: Mar., 212-215

Immune complex assays, in diagnosis of occupational lung disease, 1984: Sept., 532–533

Immune disorder(s), laboratory dignosis of, 1983: Dec., 745–761

Immune globulin, prophylaxis, for hepatitis, 1982: Mar., 246-248

Immune response. See also Inflammatory response.

in graft rejection, 1983: Dec., 764–765 prostaglandins and, 1983: Dec., 700–701 tissue, symposium on, 1983: Dec., 577–817

Immunity, cell-mediated, in burn injury, 1983: Dec., 801–802

Immunization, active, for hepatitis, 1982: Mar., 248

passive, for hepatitis, 1982: Mar., 246–248 Immunoassay(s), antibody-gel techniques of, 1984: June, 347–348

enzyme, in viral respiratory infection, 1982: June, 389

in study of hemostasis, 1984: June, 345–361 in toxicologic analysis, 1983: June, 374–375 sensitivity of, 1984: June, 346

Immunocytochemistry, for hormone receptor measurement, 1984: Dec., 823

Immunodeficiency syndrome, acquired. See Acquired immunodeficiency syndrome (AIDS).

Immunodiffusion reactions, in diagnostic of occupational lung disease, 1984: Sept., 527–531

Immunoelectrophoresis, in diagnosis of occupational lung disease, 1984: Sept., 530–531

radiotissue, for alpha-fetoprotein, 1982: Sept., 443-444

Immunoenzymatic methods, in cancer, 1982: Sept., 581–582

Immunofluorescence techniques, direct, in Legionella infection, 1982: June, 357–361

in cancer, 1982: Sept., 580-581

in chlamydial respiratory infection, 1982: June, 377–378

in detection of autoantibodies, 1983: Dec., 757–758 indirect, in Legionella infection, 1982: June, 350-356

in viral respiratory infection, 1982: Iune. 387-389

Immunogenicity, pretransplantation alteration of, 1983: Dec., 767-768

Immunoglobin(s). See also Antibody(ies). detection, by immunofluorescence, 1983: Dec., 757-758

effect of phagocytosis, in burn injury, 1983: Dec., 806-807

in cytolysis, 1982: Mar., 212-215

Immunologic stain(s), in Pneumocustis infection, 1982: June, 403

Immunologic techniques, in diagnosis of occupational lung disease, 1984: Sept., 523-538

preanalytic factors in, 1983: Sept., 535 Immunology, organ transplantation and, 1983: Dec., 763-778

prostaglandins and, 1984: Dec., 795

Immunomodulation, pretransplantation, 1983: Dec., 770

Immunopathology, tissue, symposium on, 1983: Dec., 577-817

Immunoperoxidase techniques, in detection of autoantibodies, 1983: Dec., 758-759 indirect, for human chorionic gonadotropin, 1982: Sept., 443

Immunosuppressive factors, in burn injury,

1983: Dec., 802-804 Immunosuppressive therapy, complications

of, 1983: Dec., 772-773 pretransplantation, 1983: Dec., 768-770

Incident reports, 1983: Sept., 476 Indomethacin, in inflammatory response, 1983: Dec., 688, 707

Infants, hemangiopericytomas in, 1984: Mar., 145, 148

newborn, level of antithrombin III activity in, 1984: June, 257

purpura fulminans in, 1984: June, 272 sudden death, 1983: June, 338-342

Infarction, myocardial. See Myocardial infarction.

Infection, chlamydial, laboratory diagnosis of, 1982: June, 371-382

fungal, in respiratory tract, laboratory diagnosis of, 1982: June, 321-342

hepatic, transfusion-transmitted, 1982: Mar., 233-252

Legionella, laboratory diagnosis of, 1982: June, 343-369

mycobacterial, laboratory diagnosis of, 1982: June, 305-319

nosocomial respiratory, laboratory diagnosis of, 1982: June, 415-423

opportunistic fungal, laboratory diagnosis of, 1982: June, 407-413

pleuropulmonary, laboratory diagnosis of, 1982: June, 285-303

Pneumocystis, laboratory diagnosis of, 1982: June, 393-406

respiratory, invasive diagnostic techniques in, 1982: June, 269-283

laboratory diagnosis of, 1982: June, 259-423

viral respiratory, laboratory diagnosis of, 1982: June, 383-391

Infection control, role of laboratory in, 1982: June, 415-423

Infertility, evaluation of the couple, 1984: Dec., 723-725

Inflammation, prostaglandins and, 1984: Dec., 795-796

Inflammatory cell(s). See also specific cell type, as Neutrophil(s); Macrophage(s); Monocyte(s).

neutral proteinases of, 1983: Dec., 645-666

Inflammatory disease, macrophage arachidonic acid metabolites in, 1983: Dec.,

normal proteinases in, 1983: Dec., 645-666

Inflammatory response, endothelium and, 1983: Dec., 577-598

in burn injury, 1983: Dec., 801-815 in lung, 1983: Dec., 601-617

macrophage arachidonic acid metabolites in, 1983: Dec., 684-685

mediators of, 1983: Dec., 577-592, 619-643

neutrophils and, 1983: Dec., 779-800 platelets and, 1983: Dec., 667-676 prostaglandins and, 1983: Dec., 695-717

Information format(s). See Report format(s). Information processing, analysis, in clinical laboratory, 1983: Mar., 11-12, 38, 79-100, 236

in clinical laboratory vs. anatomic pathology, 1983: Mar., 134

Information requirements, in clinical laboratory, 1983; Mar., 220-229. See also Data elements; Data bases.

Information systems computerized. See Computer information systems.

Ink, ingestion of, 1984: Sept., 592 Insecticides, ingestion of, 1984: Sept.,

Instrumentation, evaluation of, 1983: Sept.,

financial justification and cost analysis of, 1983: Sept., 437

for stat testing, 1983: Sept., 501 operational characteristics of, 1983: Sept.,

quality control for, 1983: Sept., 549 requirements for, analysis of, 1983: Sept.,

427-431 Insulin, sensitivity, estimation of, 1982: Dec., 708

Insulin (Continued)

serum, measurement of, in diabetes and hypoglycemia, 1984: Dec., 751 Interfacial tension, cell-cell interactions and,

1982: Mar., 162-163

Interferon, endotoxin-induced, in burn injury, 1983: Dec., 803

Interpretive reporting, 1984: Mar., 41–60 benefits of, 1984: Mar., 53–56 concerns about, 1984: Mar., 56 in clinical laboratory, 1983: Mar., 205–217 Interpretive reports, 1984: Mar., 49–53

Interval, occult, of laboratory test, 1982:

Dec., 852-854

Iron deficiency anemia, laboratory evaluation of, 1982: Dec., 751-777

Iron poisoning, acute, in children, 1984: Sept., 575–586

Jaundice, hemolytic disease of newborn and, 1982: Mar., 115

Job descriptions, for clinical laboratory, 1983: Sept., 456

Job grades, for clinical laboratory, 1983:
 Sept., 457
 Joint Commission on Accreditation of Hospi-

tals, 1983: Sept., 447

Joint(s), aspiration biopsy of, 1984: Mar., 96

Kell system, 1982: Mar., 143–144 Ketones, neurotoxicity of, 1984: Sept., 494–495

Kidney, aspiration biopsy of, 1984: Mar., 94 failure, after transfusion, 1982: Mar., 225 function, plants affecting, 1984: Sept., 605–606

transplantation, 1983: Dec., 771–772 HLA typing in, 1982: Mar., 125–129 Kinin(s), in anaphylaxis, 1983: Dec., 620

in endotoxin-induced lung injury, 1983: Dec., 730–731

Kininogen, immunoassay of, 1984: June, 355 Klinefelter syndrome, cytogenetic evaluation, 1984: Dec., 839

L-Asparaginase, effect on antithrombin III synthesis, 1984: June, 262

L-Thyroxine, free, measurement of, 1984: Dec., 660

L-Thyroxine, measurement of, 1984: Dec., 657–658

Labor laws, federal, 1983: Sept., 446 Laboratory. See also Clinical laboratory; Laboratory medicine. analysis, in planning for automated system, 1983: Mar., 3-18

anatomic pathology, 1983: Sept., 477 clinical, communications in, 1982: Dec., 803–819

computer information systems in (symposium), 1983: Mar., 3-251. See also Computer information systems.

organization of, 1984: Mar., 47–49 role in diagnosis of respiratory infection, 1982: June, 259–423

utilization of, 1982: Dec., 891–901 cost analysis of, 1983: Sept., 425 data, interpretive reporting of, 1984:

Mar., 41–60. See also Interpretive reporting.

design of, specifications for, 1983: Sept., 492

extent of mycobacterial services, 1982: June, 310

functional status of, analysis of, 1983: Sept., 423–427

planning and design for, 1983: Sept., 486

goals of, 1983: Sept., 426 hematology, 1983: Sept., 477

management, automated, 1983: Mar., 149-163

measurement systems in, 1983: Sept., 553–570

microcomputer-based automation of, 1983: Mar., 56–57

symposium on, 1983: Sept., 411–570 nuclear medicine, safety regulations for, 1983: Sept., 474–476

planning and design of, 1983: Sept., 483–496

problems in, 1983: Sept., 493 quality control for, 1983: Sept., 541–551 reference selection of, 1983: Sept., 507–521

role in nosocomial infection, 1982: June, 415-423

technology. See *Technology* and under specific procedures.

toxicology, 1983: June, 367–384, 385–396 utilization patterns, automated management of, 1983: Mar., 156–157

cost analysis of, 1983: Mar., 189–193 work-in-process workload, reduction of, 1983: Mar., 92–98

workload analysis of, 1983: Sept., 424 Laboratory information systems. See also Computer information systems, in clinical laboratory.

linkage with hospital information system, 1983: Mar., 219–231

request for proposal, 1983: Mar., 19-25 user-designed, 1983: Mar., 31, 35-50

Laboratory measurements. See also Laboratory tests.

in cancer, assessment of, 1982: Sept., 657-678

in evaluation of hemostasis, 1982: Sept., 616–617

in malignant disease, symposium on, 1982: Sept., 431-678

of collagen metabolites, 1982: Sept., 519–522

of eicosanoids, 1983: Dec., 699–700 of glycoproteins, 1982: Sept., 472–474 of polyamines, 1982: Sept., 508–510

Laboratory safety, regulation of, 1983: Sept., 445, 480

requirements for, 1983: Sept., 465–482 selected publications for, 1983: Sept., 481 Laboratory test(ing), accuracy of, determining, 1983: Sept., 417

clinical, evaluation of, 1982: Dec.,

821-833 computerized functions in, 1983: Mar., 102-103

costs of, 1983: Sept., 413

diagnostic errors and, 1982: Dec., 779-787

effectiveness, predictive value and, 1982: Dec., 685–699

experimental investigation of, 1983: Sept., 416-419

for hyper- and hypoglycemia, 1984: Dec., 745–761

in autoimmune disorders, 1983: Dec., 745–761

in combination, predictive value model in, 1982: Dec., 695–698

in evaluation of endocrine function, 1982: Dec., 803–819

in monitoring disease, timing of, 1982: Dec., 851-870

in series, functions of, 1982: Dec., 835–850

interpretive reporting and, 1983: Mar., 210-214 marketing, 1983: Sept., 420

multiple, correlation of, 1982: Dec.,

884–887 interpretation of, 1982: Dec., 814–815

selection of, 1982: Dec., 871-890 new, planning and instituting, 1982: Dec., 751-777; 1983: Sept., 413-422

objectives, 1983: Mar., 206–208
 of thyroid function, 1984: Dec., 657–668
 controversies in, 1984: Dec., 671–682

precision of, determining, 1983: Sept.,

preliminary investigation of, 1983: Sept., 412

rational approach to, 1984: Mar., 25-39

reference range of, 1983: Sept., 419 reference values in, 1984: Mar., 61-70 report formats, 1983: Mar., 79-10. See also Report format(s).

requests for, 1984: Mar., 42-47 selection, biodynamic models and, 1982:

Dec., **701–715** by multivariate analysis, *1982*: Dec., **735–750**

in clinical problems, 1982: Dec., 789–802. See also under specific problems, as Myocardial infarction. pattern recognition in, 1982: Dec.,

717–734 strategies for, symposium on, 1982: Dec., 685–901

steps in, 1984: Mar., 43

usage, surveillance of, 1982: Dec., 891-901

Lactate dehydrogenase, in cancer, 1982: Sept., 487–488

Lactoferrin, deficiency, in neutrophil dysfunction, 1983: Dec., 791–792

Laetrile, cyanide intoxication caused by, 1984: Sept., 606

Laundering agents, ingestion of, 1984: Sept., 592–593

Laurell rocket electroimmunoassay, 1984: June, 347

Lavage, bronchoalveolar, in respiratory infection, 1982: June, 276-277

Lead, neurotoxicity of, 1984: Sept., 489-491 Lead poisoning, in children, 1984: Sept., 471-472

Leadership, development of, 1983: Sept., 452

Legionella, classification of, 1982: June, 345 isolation of, 1982: June, 345–350Legionella infection(s), laboratory diagnosis

of, 1982: June, 343–369

Legionnaire's disease, laboratory diagnosis of, 1982: June, 343–369

Lethality, of toxic substances, determination of, 1984: Sept., 508-509

Leukapheresis, therapeutic, 1982: Mar., 97–100

Leukemia, acute lymphoblastic, classification of, 1982: Sept., 582–583 acute myeloblastic, classification of, 1982:

Sept., 584 chronic, leukapheresis and, 1982: Mar., 99–100

chronic lymphocytic, classification of, 1982: Sept., 584–585

CK₁ activity in, 1982: Sept., 499–500 classification, immunologic techniques in, 1982: Sept., 579–597

lysozyme activity in, 1982: Sept., 484 TdT activity in, 1982: Sept., 484-485 Leukocyte(s). See Neutrophil(s); Granulo-cyte(s); Lymphocyte(s).

Leukocyte differentials, definition of bands and polys on, 1984: Mar., 72–74 fluctuations in, 1984: Mar., 83, 84

quality of smear in, 1984: Mar., 72 value of, 1984: Mar., 71-87

Leukotriene(s), in anaphylaxis, 1983: Dec., 621-625

in endotoxin-induced lung injury, 1983: Dec., 728

in neutrophil-mediated lung injury, 1983: Dec., 610–611

in neutrophil stimulation, 1983: Dec., 786–787

production of, 1983: Dec., 681-684 Lightning, injury from, 1983: June, 311,

352–353
"I ikelihaad quotiente" in test evaluation

"Likelihood quotients," in test evaluation, 1982: Dec., 759-764

Lipid(s). See also specific substances, as Prostaglandin(s); Platelet-activating factor.

analysis of, 1983: Sept., 525

metabolism, in neutrophil stimulation, 1983: Dec., 786-787

Liposarcoma, electronmicroscopic diagnosis of, 1984: Mar., 148–151, 152–155

Lipoxygenase pathway, inhibition, 1983: Dec., 728–729

of arachidonate metabolism, 1983: Dec., 680–681

Litigation, product liability, 1983: June, 397 role of pathologist in, 1983: June, 397-405 Liver, acute necrosis of, heparin therapy in,

1984: June, 428 platelet function in, 1984: June, 421 autoimmune diseases of, 1983: Dec., 749–750

cancer, γGTP activity in, 1982: Sept., 483-484

LDH activity in, 1982: Sept., 487–488 disease of, antithrombin III in, 1984: June, 426

chronic, dysfibrinogenemias in, 1984: June, 422-424

coagulation disorders in, laboratory assessment of, 1984: June, 419–441 treatment of, 1984: June, 429–430 coagulation factors in, 1984: June,

421–426

coagulation studies in, application and significance of, 1984: June, 432–433

disseminated intravascular coagulation in, 1984: June, 428–429

Factor VII deficiency with, 1984: June, 238

fibrinolytic activity in, 1984: June, 426–427

hemostatic abnormalities in, 1984: June, 419

in primates, CEA clearance and, 1982: Sept., 459–467

platelet function in, 1984: June, 420-421

protein C deficiency with, 1984: June, 272

test selection in, 1982: Dec., 708–709, 735–750, 799

failure, acute, assessment of clotting factor activity in, 1984: June, 424-426

inflammation, transfusion-transmitted, 1982: March, 233–252

injury to due to environmental agents, 1984: Sept., 483–488

from firearms, 1983: June, 285–287 metastatic carcinoma of, clotting factor abnormalities in, 1984: June, 430

needle biopsy of, 1984: Mar., 95 plants affecting, 1984: Sept., 605 transplantation, 1983: Dec., 772–773

Lobelia inflata, overdose, 1984: Sept., 611

Lung, abscess, radiographic appearance, 1982: June, 289–290

anaerobic infection, diagnosis of, 1982: June, 285–303

aspiration, in respiratory infection, 1982: June, 278–279

aspiration biopsy of, 1984: Mar., 93 biopsy, in *Pneumocystis* infection, 1982: June, 395–396

in respiratory infection, 1982: June, 275–276

cancer, CK₁ activity in, 1982: Sept., 496–497

hydroxyproline in, 1982: Sept., 532-534 screening for, 1982: Sept., 646

disease, occupational, immunologic techniques in diagnosis, 1984: Sept., 523-538

elastic recoil of, effect of emphysema on, 1984: Sept., 551–555

heart and, transplantation, 1983: Dec., 774

injury, following skin burns, 1983: Dec., 810-812

mechanisms of, 1983: Dec., 601–617 septicemia and, 1983: Dec., 719–744

open biopsy, in respiratory infection, 1982: June, 279–280

Lupus erythematosus, systemic, antibody markers of, 1983: Dec., 754-757 prostaglandins and, 1983: Dec., 705-706

test selection in, 1982: Dec., 880–884 Luteal phase defects, in infertility, 1984: Dec., 725–726

Lutheran system, 1982: Mar., 143

Lymph node(s), metastatic, as predictor of recurrent breast cancer, 1982: Sept., 661–664

Lymphocyte(s), depletion of, pretransplantation, 1983: Dec., 769–770 effect of burn injury on, 1983: Dec.,

801-802

in pretransplantation crossmatch, 1983: Dec., 765–766

thymus-dependent, in autoimmune disorders, 1983: Dec., 746

Lymphoma, malignant, classification of, immunologic techniques in, 1982: Sept., 579–597

secondary, aspiration biopsy of, 1984: Mar., 93

Lysozyme, in leukemia, 1982: Sept., 484

Macrophage(s), activation, arachidonic acid metabolism and, 1983: Dec., 677–694 neutral proteinases of, 1983: Dec., 650–652

role in proteolysis, 1983: Dec., 657–658 suppressive effects of prostaglandins on, 1983: Dec., 685

Maintenance, of laboratory information system, 1983: Mar., 235. See also Hardware: Software.

Malignant disease. See also Cancer. laboratory measurements in, symposium

on, 1982: Sept., 431-678 Malignant fibrous histocytoma, electronmicroscopic diagnosis of, 1984: Mar., 123-130

Malignant lymphoma, secondary, aspiration biopsy of, 1984: Mar., 93

Malignant schwannoma, electronmicroscopic diagnosis of, 1984: Mar., 137–141 Malnutrition, decreased antithrombin III

synthesis due to, 1984: June, 262
Management, automated functions, in clini-

Management, automated functions, in clinical laboratory, 1983: Mar., 149–163 of laboratory, symposium on, 1983: Sept.,

of medical laboratories, measurement systems in, 1983: Sept., 553-570

Manual versus automated information systems, cost analysis, 1983: Mar., 67-76 in blood banking, 1983: Mar., 126-130

Marrow, transplantation, HLA typing in, 1982: Mar., 128–129

Mass screening, criteria for, 1982: Sept., 629–630

for cancer, 1982: Sept., 627–638 Massachusetts General Hospital microbiology system, 1983: Mar., 106–107

 Matches, ingestion of, 1984: Sept., 594
 Mathematical model(s), biodynamic, in test selection, 1982: Dec., 701–715

for timing of repeated tests, 1982: Dec., 851-870

in cancer screening, 1982: Sept., 634-635

in monitoring cancer, 1982: Sept., 657-678

Mean corpuscular volume, in iron deficiency anemia, 1982: Dec., 758–764

Mean platelet volume, 1984: June, 292–293
Mean time between failures (MTBF), in laboratory information system, 1983: Mar., 167

Mean time to repair (MTTR), in laboratory information system, 1983: Mar., 167

Measurement systems, in management of medical laboratories, 1983: Sept., 553-570

Mechanical explosions, 1983: June, 309–310 Meclofenamate sodium, pulmonary effects, following endotoxemia, 1983: Dec., 725–727

Media, culture, in isolation of anaerobes, 1982: June, 297–298

in isolation of fungi, 1982: June, 326-328

in isolation of Legionella, 1982: June, 345–350

Mediator(s), of endotoxin-induced lung injury, 1983: Dec., 719-744

of inflammatory response. See specific substance, as *Histamine*.

Medicaid, 1983: Sept., 442

Medical care, computerized evaluation of, 1983: Mar., 179–204

Medical decision-making, computer-supported, 1983: Mar., 183-189

Medical diagnosis, laboratory testing in. See under Laboratory testing.

Medical quality assurance, efficacy of autopsy in, 1984: Mar., 165-184

Medical quality assurance programs, 1984: Mar., 177–179

Medicare, 1983: Sept., 441 Medulla. See Marrow.

Membrane, of red blood cell, 1982: Mar., 155-159

Meninges, hemangiopericytomas in, 1984: Mar., 145, 148

Mercury, neurotoxicity of, 1984: Sept., 493-494

Mesothelioma, fibrous, electronmicroscopic diagnosis of, 1984: Mar., 130-137

Message(s), computer-generated, 1983: Mar., 183–186. See also Report format(s).

Metabolism, of xenobiotics, in children, 1984: Sept., 471

Metabolite(s), of arachidonic acid. See specific substances, as *Prostaglandin(s)*;

Leukotriene(s).

Metastases, to bone, prediction of, in breast cancer, 1982: Sept., 525–527 in lung cancer, 1982: Sept., 532–534 in multiple myeloma, 1982: Sept.,

in prostatic cancer, 1982: Sept., 531

Metyrapone test, for hypercortisolism, 1984: Dec., 691-692

MGH Utility Multi-Programming System (MUMPS), 1983: Mar., 6-7, 106-107 Microagglutination (MA) test, in Legionella

infection, 1982: June, 354

Microbiologic hazards, 1983: Sept., 473 Microbiologic test(ing), preanalytic factors in, 1983: Sept., 531–535

Microbiology, computer information systems in, 1983: Mar., 101-110

microcomputer-based systems in, 1983: Mar., 56

laboratory, safety requirements of, 1983: Sept., 473

Microbiology specimen brush, 1982: June, 293–294

Microcomputers, in clinical laboratory, 1983: Mar., 51-62

Microimmunofluorescence (MIF), in chlamydial respiratory infection, 1982: June, 377–378

Microprocessor(s), 1983: Mar., 53 in user-designed system, 1983: Mar., 39–40

Microscopy, in evaluation of sputum, 1982: June, 260–262

in fungal respiratory infection, 1982: June, 328–329

Milk protein(s), in breast cancer, 1982: Sept., 545

Minicomputer(s), in user-designed system, 1983: Mar., 40

Minimum bactericidal concentration, 1984: Mar., 111

Missile wounds. See Firearm wounds. MNSs system, 1982: Mar., 141-142

Model(s), biodynamic, in test selection, 1982: Dec., 701–715

mathematical, for timing of repeated tests, 1982: Dec., 851–870

in cancer screening, 1982: Sept., 634–635

in monitoring cancer, 1982: Sept., 657-678

Monitoring, of test use, 1982: Dec., 891–901 of patient, serial testing in, 1982: Dec., 842–847

timing of laboratory tests in, 1982: Dec., 851–870

Monkshood, overdose, 1984: Sept., 612 Monoclonal antibodies, for estrogen receptor measurements, 1984: Dec., 827

in autoimmune disorders, 1983: Dec., 759-760

in organ transplantation, 1983: Dec., 777 Monocyte(s), neutral proteinases of, 1983: Dec., 649–650

role in proteolysis, 1983: Dec., 657–658 Mucous membranes, irritation of, by plants, 1984: Sept., 604–605 Multiple testing, evaluation of efficiency, 1982: Dec., 760-764

predictive value model in, 1982: Dec., 695–698

selection of, 1982: Dec., 871-890

Multiple univariate analysis, in test selection, 1982: Dec., 737-738

Multiple variate analysis, in test selection, 1982: Dec., 735–750

Mumps, 1983: Mar., 6-7, 106-107

Muramidase, in leukemia, 1982: Sept., 484
 Muscle, alcohol levels in, 1983: June, 387
 injury, from firearms, 1983: June, 283–285

Muscular disease, autoimmune, 1983: Dec., 753

Myasthenia gravis, antibody markers of, 1983: Dec., 753

Mycobacterial, nomenclature, 1982: June, 308–309

susceptibility testing of, 1984: Mar., 115 Mycobacterial infection, laboratory diagnosis of, 1982: June, 305–319

Mycosis(es), of respiratory tract, laboratory diagnosis of, 1982: June, 321–342, 407–413

Myeloma, multiple, hydroxyproline in, 1982: Sept., 534–536

Myocardial infarction, size, prediction of, 1982: Dec., 710

test selection in, 1982: Dec., 707–708, 791–792

Nafazatrom, in inflammatory response, 1983: Dec., 688

Nails, or fingers. See Fingernail(s). Nail polish remover, ingestion of, 1984: Sept., 593

National Institute of Health (NIH) microbiology system, 1983: March, 107

Needle biopsy. See also Aspiration cytology, 1984: Mar., 89-98

Neisseria gonorrhoeae, penicillin susceptibility of, 1984: Mar., 101

susceptibility testing of, 1984: Mar., 110 Neonate, chlamydial pneumonitis in, 1982: June, 372

Neoplastic disease. See Cancer.

Nephelometry, in diagnosis of occupational lung disease, 1984: Sept., 528

Nephrotic syndrome, decreased antithrombin III survival with, 1984: June, 263

Networking, of computer information systems, 1983: Mar., 200

of HIS/LIS systems, 1983: Mar., 229–230 Neurotoxic substances, 1984: Sept., 489–497 Neutrophil, altered function, in burn injury,

1983: Dec., 804–808 chemotaxis, in burn injury, 1983: Dec., 804–806 disorders of stimulus-response coupling, 1983: Dec., 779–800

interaction with platelets, in inflammatory response, 1983: Dec., 673

neutral proteinases of, 1983: Dec.,

647-649

role in lung injury, 1983: Dec., 601–617 role in proteolysis, 1983: Dec., 654–657 stimulation, mechanisms of, 1983: Dec., 780–787

vascular permeability and, 1983: Dec., 607-612

Newborn. See also Neonate.

antithrombin III activity in, 1984: June, 257

purpura fulminans in, 1984: June, 272 Newman's grammar of assent, 1984: Mar., 12-14

Nicotine poisoning, in tobacco pickers, 1984: Sept., 472

Non-Hodgkin's lymphoma(s), classification of, 1982: Sept., 585–589

Nonsteroidal anti-inflammatory drug(s) (NSAIDs), effect on prostaglandins, 1983: Dec., 706–708

Nontoxic ingestions, 1984: Sept., **587–602** Nonsteroidal anti-inflammatory drug(s) (NSAIDs), in asthmatics, 1983: Dec., 628

Nordihydroguaiaretic acid, in inflammatory response, 1983: Dec., 688
Nosocomial infection, respiratory, laboratory

Nosocomial infection, respiratory, laboratory diagnosis of, 1982: June, 415-423

Nuclear exchange assays, for estrogen receptor measurements, 1984: Dec., 826–827 Nuclear medicine, safety regulations for,

1983: Sept., 474 5'Nucleotidase, in cancer, 1982: Sept., 482 Nucleotide(s), cyclic. See Cyclic AMP; Cyclic GMP.

Occupational health standards, risk assessment in, 1984: Sept., 475–482

Ocular disease, aspiration cytology in, 1984: Mar., 90

Odor(s), drugs and, 1983: June, 376 Ohm's law, 1983: June, 344

Oliguria, fluid therapy in, 1982: Mar., 56–57 Oncology, prostaglandins and, 1984: Dec., 795

Opsonin(s), effect on phagocytosis, in burn injury, 1983: Dec., 806–807

Oral cavity, indigenous flora in, 1982: June, 286–287

Oral contraceptives, effect on antithrombin III activity, 1984: June, 262

Organ(s) body, alcohol levels in, 1983: June, 387

drug levels in, 1983: June, 369-370

injury to, in battered child, 1983: June, 336

preservation, for transplantation, 1983: Dec., 766

transplantation, immunologic principles and, 1983: Dec., 763-778

Orphan data, 1984: Mar., 178

Osteocalcin, in assessment of bone metabolism, 1984: Dec., 769

Osteopenia, laboratory evaluation of, 1984: Dec., 763–774

Ovary, germ cell tumor of, markers for, 1982: Sept., 453-454

Overdose. See Poisoning; Forensic toxicology.

Oxidant(s), as proteinase inhibitors, 1983: Dec., 653

generation of, by granulocytes, 1983: Dec., 737

in inflammatory response, 1983: Dec., 583–585

in lung injury, 1983: Dec., 812

in neutrophil-mediated lung injury, 1983: Dec., 611-612

in neutrophil stimulation, 1983: Dec., 781–782

Paint, as evidence, 1983: June, 364 ingestion of, 1984: Sept., 596
 PALI, 1983: Mar., 180

Pancreas, cancer, enzymatic activity in, 1982: Sept., 482–483

immunodiagnosis of, 1982: Sept., 567–578

test selection in, 1982: Dec., 876-878 transplantation, 1983: Dec., 774-776

Pancreas-specific antigen (PaA), in pancreatic cancer, 1982: Sept., 567-578

Parallel testing, of laboratory information system, 1983: Mar., 241 of user-designed system, 1983: Mar., 47 predictive value model in, 1982: Dec.,

695–698 selection of, 1982: Dec., 871–890

Parathyroid disease, test selection in, 1982: Dec., 809–812

Parathyroid hormone, ectopic, in hypercalcemia, 1984: Dec., 779

measurement of, in assessment of mineral metabolism, 1984: Dec., 769-770

Parenteral alimentation, vitamin K and Factor VII deficiency in, 1984: June, 238

Paternity testing, HLA typing in, 1982: Mar., 133

Pathogen(s), See specific etiologic agent. Pathologist, diagnostic process and, 1984:

Mar., 3–23 Pathology, anatomic, computer information systems in, 1983: Mar., 133–147 Pathology (Continued)

forensic, symposium on, 1983: June, 257-405

training in, fifth-year controversy, 1984: Mar., 185-200

Patient care, computerized evaluation of, 1983: Mar., 179-204

enhancement, in computerized laboratory, 1983: Mar., 82–88

Pattern recognition, in test interpretation, 1982: Dec., 814–815 in test selection, 1982: Dec., 717–734

Pay scales, determination of, 1983: Sept., 458

Pellagra, in carcinoid syndrome, 1984: Dec., 809

Penicillinase testing, 1984: Mar., 114 Penicillin, in anaerobic respiratory infection,

1982: June, 300 Pennyroyal oil, overdose, 1984: Sept., 610 Percutaneous lung aspiration (PLA), in res-

piratory infection, 1982: June, 278–279 Peripheral devices, in laboratory information system, 1983: Mar., 46

in user-designed system, 1983: Mar., 42, 45

"Personal computers," 1983: Mar., 3-4, 51-62

Personnel, in automated clinical laboratory, cost analysis, 1983: Mar., 72–74 selection, 1983: Mar., 236

training, 1983: Mar., 24, 47, 240, 245 of medical laboratory, management of, 1983: Sept., **553–570**

nontesting activities, 1983: Sept., 560–561

Personnel management, 1983: Sept., 451-463

counseling in, 1983: Sept., 462 disciplinary action and, 1983: Sept., 462 performance evaluation in, 1983: Sept., 461

style of, 1983: Sept., 453 tools for, 1983: Sept., 454

Pesticides, human exposure to, 1984: Sept., 510–514, 596

Petroleum distillate hydrocarbon, ingestion of, 1984: Sept., 597

Phagocyte(s). See Macrophage(s); Neutrophil(s); Monocyte(s).

Phagocytosis, antibody-mediated, 1982: Mar., 211–215

complement and, 1982: Mar., 216–218 inhibitors, in burn injury, 1983: Dec., 806–807

Pheochromocytoma, diagnosis of, 1984: Dec., 703–716

test selection in, 1982: Dec., 793–795 Phosphatase, acid type, in prostatic cancer, 1982: Sept., 480–481; 1982: Dec., 692–695 alkaline type, in cancer, 1982: Sept., 481-482

Phosphohexose isomerase, in cancer, 1982: Sept., 488–489

Phosphorous, measurements of, in assessment of mineral metabolism, 1984: Dec., 769

Pituitary, tumors of, 1984: Dec., 643–654 Plants, exposure to, evaluation of, 1984: Sept., 603–614

ingestion of, 1984: Sept., 599–601 presenting as gastroenteritis, 1984: Sept., 605

Plasma, exchange. See *Plasmapheresis*. fresh frozen, transfusion, 1982: Mar., 13-14

thrombin inhibition by, nomenclature for, 1984: June, 246

Plasma antithrombin III, assays for, 1984: June, 265, 266

Plasmapheresis, in hemolytic disease of newborn, 1982: Mar., 119–120 physiology of, 1982: Mar., 89–91 pretransplantation, 1983: Dec., 769–770 therapeutic, 1982: Mar., 91–97

Plasminogen, assay of, synthetic substrate for, 1984: June, 390

measurement of, 1984: June, 298 Plasminogen activator, in extracellular tissue degradation, 1983: Dec., 649–650

Platelet(s), binding of von Willebrand factor to, 1984: June, 306 in complement activation, 1983: Dec.,

670-671 in endotoxin-induced lung injury, 1983:

Dec., 739–740 in inflammatory response, 1983: Dec.,

667-676 interaction with microorganisms, in inflammatory response, 1983: Dec., 672 interaction with neutrophils, in inflamma-

tory response, 1983: Dec., 673 Platelet-activating factor, in anaphylaxis, 1983: Dec., 621–625

in inflammatory response, 1983: Dec., 669–670

production of, 1983: Dec., 626

Platelet aggregation, test for, 1984: June, 295

von Willebrand factor-induced, 1984: June, 324–326

Platelet antibody tests, 1984: June, 293 Platelet-blood vessel interaction, in von Willebrand's disease, 1984: June, 307–308

Platelet count, 1984: June, 292–293 in platelet-type von Willebrand's disease, 1984: June, 320

Platelet-derived growth factor, chemotactic activity of, 1983: Dec., 668, 671–672

Platelet factor(s), 1982: Sept., 602 chemotactic activity of, 1983: Dec., 668 Platelet Factor III availability, test for, 1984: June, 295

Platelet fibrinogen, 1984: June, 410

Platelet function, in acute hepatic necrosis, 1984: June, 421

in liver disease, 1984: June, 420–421 in von Willebrand's disease, 1984: June, 319–331

tests of, 1984: June, 294–295 in platelet-type von Willebrand's disease, 1984: June, 321

Platelet-specific proteins, immunoassay of, 1984: June, 351–353

Platelet transfusion, 1982: Mar., 10-13 HLA typing in, 1982: Mar., 129

Plateletpheresis, therapeutic, 1982: Mar., 100–101

Pleura, anaerobic infection, laboratory diagnosis of, 1982: June, 285–303 fibrous tumor of, electronmicroscopic di-

agnosis of, 1984: Mar., 130–137 Plumbism, due to lead poisoning, 1984: Sept., 490–491

Pneumocystis infection, laboratory diagnosis of, 1982: June, 393-406

Pneumonia, bronchoalveolar lavage and, 1982: June, 276–277

fungal, laboratory diagnosis of, 1982: June, 407–413 Legionella, laboratory diagnosis of, 1982:

June, 343–369 nosocomial, laboratory diagnosis of, 1982:

June, 415–423
Pneumonitis, chlamydial, laboratory diagno-

sis of, 1982: June, 371-382 Poison(s), analysis of. See Toxicologic analy-

drug. See under specific drugs.

ethyl alcohol, toxicologic analysis in, 1983: June, 385–396

toxic concentrations of, 1983: June, 381–382

victim of, role of emergency physician in treatment of, 1984: Sept., 615–625 Poison control centers, 1984: Sept., 561–573

Polyamine(s), in malignant disease, 1982: Sept., 507-518

Polycystic ovarian syndrome, 1984: Dec., 725

Polyethylene glycol assay, in diagnosis of occupational lung disease, 1984: Sept., 532–533

Polymorphonuclear leukocyte(s). See Neutrophil(s).

Polys, microscopic definition of, 1984: Mar., 72-75

Postmortem examination, in medical quality assurance, 1984: Mar., 165–184
Powder tattooing, 1983: June, 266–267

Precision, in quality control studies, 1983: Sept., 547 Predictive value, effect of test correlation on, 1982: Dec., 884–887 in test evaluation, 1982: Dec., 685–699,

753–764 of screening test, 1982: Sept., 643

Pre-eclampsia, decreased antithrombin III survival with, 1984: June, 262

Pregnancy, antithrombin III deficiency with, 1984: June, 260

fatty liver of, antithrombin III activity with, 1984: June, 262

free thyroxine assays and, 1984: Dec., 679–680

heparin therapy during, 1984: June, 260

Prekallikrein, immunoassay of, 1984: June, 356

in liver disease, 1984: June, 424 Pressure, effects, in explosions, 1983: June, 314

Pretransfusion testing, type and screen in, 1982: Mar., 169-179

Prevalence, of disease, effect on test performance, 1982: Dec., 754-755

Primer, for firearm cartridges, 1983: June, 258-259

residue from, as evidence, 1983: June, 358–360

Probability, of disease, estimating, 1984: Mar., 28–32 posterior, defined, 1982: Dec., 688–689

prior, defined, 1982: Dec., 688–689 prior, defined, 1982: Dec., 688–689 Problem solving, clinical, in laboratory,

1982: Dec., 789–802 process of, 1982: Dec., 701–702 Product liability, 1983: June, 397–405 Program(s). See Software.

Programmed accelerated laboratory investigation (PALI), 1983: Mar., 180

Programming languages, for microcomputers, 1983: Mar., 53

Proinsulin, measurement of, in diabetes and hypoglycemia, 1984: Dec., 751

Projectile(s), firearm. See Bullets; Cartridges.

Project team, for system development, 1983: Mar., 7-8, 233-234

Prolactin, hypersecretion of by pituitary adenomas, 1984: Dec., 647-649 mass effects of pituitary tumors on, 1984:

Dec., 644–645 Proposal. See Request for proposal.

Prostaglandin(s), in anaphylaxis, 1983: Dec., 621–625

in endotoxin-induced lung injury, 1983: Dec., 724–725

in human disease, 1984: Dec., **787–801** in inflammatory response, 1983: Dec., 585–586, **695–717**

in neutrophil-mediated lung injury, 1983: Dec., 605–610 Prostaglandin(s) (Continued) in neutrophil stimulation, 1983: Dec., 786–787

macrophage-derived, in inflammatory response, 1983: Dec., 684–689 production of, 1983: Dec., 680–684

Prostaglandin synthesis inhibitors, 1984: Dec., 789

Prostate, adenocarcinoma of, aspiration biopsy of, 1984: Mar., 96

Prostate, cancer, acid phosphatase in, 1982: Sept., 480-481 hydroxyproline in, 1982: Sept., 528-532 test selection in, 1982: Dec., 692-695

Protease(s), neutral, role in neutrophil-mediated lung injury, 1983: Dec., 611

Protein(s), acute phase, secretion of, model for, 1982: Dec., 710-711 synthesis of, 1982: Sept., 472-473

associated with pregnancy, in breast cancer, 1982: Sept., 548–549

complement. See Complement. cytosol, in breast cancer, 1982: Sept.,

547-548 degradation of, inflammatory cell-me-

diated, 1983: Dec., 652-658 lactic, in breast cancer, 1982: Sept., 545

Protein(s), platelet-specific, immunoassays for, 1984: June, 351–353 proteolytic fragments of, biologic activity

of, 1983: Dec., 658–659 vitamin K-dependent, 1984: June, 212–213

Protein binding, free thyroxine assays and, 1984: Dec., 678–679

1984: Dec., 678–679 Protein C, activated, physiologic substrates for, 1984: June, 269

activation of, 1984: June, 268 model for, 1984: June, 269

anticoagulant properties of, 1984: June, 268

Protein C antigen, immunoassay of, 1984: June, 356

Protein Case, 1984: June, 211 clinical disorders involving, 1984: June, 271–272

in hemostasis, 1984: June, 266–274 laboratory measurement of, 1984: June, 272–274

molecular biology of, 1984: June, 267-271 regulation of, 1984: June, 270-271

Protein-losing enteropathy, decreased antithrombin III survival with, 1984: June, 263

Protein S, in anticoagulant activity of activated protein C, 1984: June, 270

Proteinase(s), inhibitors of, 1983: Dec., 652–654

neutral, in extracellular matrix degradation, 1983: Dec., 645-666 Proteolytic enzyme(s), in extracellular matrix degradation, 1983: Dec., 645–666

Prothrombin, immunoassay of, 1984: June, 353

in evaluation of cirrhosis, 1984: June, 423 Prothrombin time, activated partial (APPT), 1984: June, 221

measurement of, 1984: June, 296 Ouick, 1984: June, 229–230

Prothrombinase, 1984, June, 211 Prothrombinase complex, hypothetical model of, 1984: June, 215

Pruritus, periumbilical, laboratory diagnosis of, 1982: Dec., 858–867

Pseudohermaphroditism, cytogenetic evaluation, 1984: Dec., 840–841

Psychologic aspects, of diagnostic process, 1984: Mar., 11–14

Pulmonary. See also Lung.

Pulmonary cancer, CK₁ activity in, 1982: Sept., 496–497

hydroxyproline in, 1982: Sept., 532-534 Pulmonary dysfunction, associated with em-

physema, 1984: Sept., 548–555 Pulmonary embolism, diagnosis and treatment of, fibrinopeptide A assays in, 1984: June, 363–380

test selection in, 1982: Dec., 792 Pulmonary emphysema, pathology of, 1984:

Pulmonary emphysema, pathology of, 1984: Sept., 539–559 Pulmonary function, following endotoxemia,

1983: Dec., 720-723Pulmonary function tests, in emphysema detection, 1984: Sept., 550

Pulmonary infection(s). See under *Infection* or specific type or agent of infection.

Purpura fulminans, neonatal, 1984: June, 272

Putrescine, in malignant disease, 1982: Sept., 507–518

Quality control, automated system, in clinical laboratory, 1983: Mar., 151–153 for the clinical laboratory, 1983: Sept., 541–551

in automated blood bank, 1983: Mar., 127–128

microbased programs, 1983: Mar., 54 of workload recording system, 1983: Sept., 562–563

Quick prothrombin time, 1984: June, 229-230

Radioallergosorbent test (RAST), for IgE antibody, in diagnosis of occupational lung disease, 1984: Sept., 526–527

Radiochemical probes, for estrogen receptor measurements, 1984: Dec., 827-828

Radiography, in battered child, 1983: June, 322, 332–333

in fire deaths, 1983: June, 298, 306 in firearm wounds, 1983: June, 269-270

Radioimmunoassays, for arginine vasopressin, 1984: Dec., 732–737

for prostatic acid phosphatase, in cancer screening, 1982: Dec., 692-695

in toxicologic analysis, 1983: June, 374–375

in viral respiratory infection, 1982: June, 389

of Factor VII antigen, 1984: June, 233 Radiology, in emphysema detection, 1984: Sept., 550

Randomized controlled trial(s) (RCT), for cancer screening programs, 1982: Sept., 633-634

Rape-homicide, collection of evidence in, 1983: June, 358, 361–362

Rational decision-making, 1984: Mar., 25–26 Reaction, Arthus, prostaglandins and, 1983: Dec., 706

Receiver operating characteristic (ROC) curve, in test evaluation, 1982: Dec., 825–832

of screening test, 1982: Sept., 641–642 Receptor measurements, 1984: Dec.,

817-833
Rectum, cancer of, screening tests for, consequences of diagnostic error, 1982:

Dec., 782–784 Recurrence, of breast cancer, prediction of, 1982: Sept., 657–678

Red blood cells. See Erythrocyte(s).

Reference interval(s), 1982: Sept., 661–664 Reference laboratory services, requirements for, 1983: Sept., 509

selection of, 1983: Sept., 507-521

Reference values, collecting, standardization and control of, 1984: Mar., 63–67 intraindividual variation in. 1984: Mar.,

utility of, 1984: Mar., 61-70

Registry(ies), of cancer incidence, 1982: Sept., 633

Reliability, of laboratory information system, 1983: Mar., 165-177

Renal failure, after transfusion, 1982: Mar., 225

Renal function, plants affecting, 1984: Sept., 605

Renal system, prostaglandins and, 1984: Dec., 792

Report format(s), in anatomic pathology, 1983: Mar., 140–142 in computerized laboratory, 1983: Mar., 79–100, 237 in microbiologic computer system, 1983: Mar., 104-106

interpretive, in computerized laboratory, 1983: Mar., 205-217

Reporting, interactive in anatomic pathology, 1983: Mar., 142-143

interpretive, in clinical laboratory, 1983: Mar., 205-217

Reproductive disorders, associated with prostaglandins, 1984: Dec., 790-791 Reproductive toxicology, 1984: Sept.,

461–467

Request for proposal (RFP), for laboratory information system, 1983: Mar., 9–10, 19–25

Requests forms, for thyroid function tests, 1984: Dec., 665

Resins, overdose, 1984: Sept., 611

Respiration, cellular, plants affecting, 1984: Sept., 606

Respiratory distress, in carcinoid syndrome, 1984: Dec., 809

Respiratory distress syndrome, adult, fluid therapy in, 1982: Mar., 39–49 inflammatory response and, 1983: Dec., 601–617

septicemia and, 1983: Dec., 719–744
Respiratory system, prostaglandins and,

1984: Dec., 793-794
Respiratory tract, exposure of to toxins, treatment of, 1984: Sept., 619-620

in children, as route of entry for toxins, 1984: Sept., 470–471

infection. Also see under etiologic agent, as Virus. invasive diagnostic techniques in, 1982:

June, 269–283 laboratory diagnosis of, 1982: June,

259–423 specimens, evaluation of, 1982: June,

259–267
upper, collection and handling of speci-

mens from, 1983: Sept., 533
Resuscitation, of emergency patients, 1982:

Mar., 53–55

Rh factor, maternal immunization to, in he

Rh factor, maternal immunization to, in hemolytic disease of newborn, 1982: Mar., 107–122

Rh immune globulin, in prevention of Rh immunization, 1982: Mar., 108–109, 113–119

Rh immunization, in hemolytic disease of newborn, 1982: Mar., 107–122 plasma exchange in, 1982: Mar., 94–95

Rh matching, in emergency cardiovascular surgery, 1982: Mar., 78–81

Rh system, 1982: Mar., 142-143

Rh typing, in emergency transfusion, 1982: Mar., 78–81 Rhabdomyosarcoma, 1984: Mar., 161 embryonal, 1984: Mar., 158

Rifle. See Firearm(s); Rifled weapons.
Rifled weapon(s), entrance wounds from,
1983: June, 264–270

wounds from, 1983: June, 257–271, 273–294. See also Firearm wounds.

Rifling, of gun barrel, 1983: June, 257 Risk assessment, in regulation of occupational health standards, 1984: Sept., 475–482

Risk-benefit analysis, in test selection, 1982: Dec., 790–791

Ristocetin response, in platelet-type von Willebrand's disease, 1984: June, 321–324

Rosettes, formation of, 1982: Sept., 580 Rule of nines, for burn estimation, 1983: June, 301

Safety, laboratory, federal regulation of, 1983: Sept., 445

publications for, 1983: Sept., 481 Safety manual, for laboratory, 1983: Sept.,

Safety regulations, for laboratory, 1983: Sept., 465–482

Salivary gland, aspiration cytology of, 1984: Mar., 92

Sarcoma, Ewing's, electronmicroscopic diagnosis of, 1984: Mar., 151, 156–157, 160, 161

Schlichter test, 1984: Mar., 111, 112Schwannoma, malignant, electronmicroscopic diagnosis of, 1984: Mar., 137–141

Screening test(s), for bleeding disorders, 1984: June, 289–290

for iron deficiency anemia, 1982: Dec., 761-775

for prostatic cancer, 1982: Dec., 692–695 mass, for cancer, 1982: Sept., 627–638 performance characteristics of, 1982: Sept., 639–656

predictive value and, 1982: Dec., 685 Security, of laboratory information system, 1983: Mar., 165–177

Senecio, overdose, 1984: Sept., 612 Sensitivity, of screening tests, 1982: Sept., 640–642

to toxic chemicals, increased, 1984: Sept., 509-510

Sensitivity analysis, in test evaluation, 1982: Dec., 774–775

Sepsis. See also Septicemia. burn injury and, 1983: Dec., 801–815 decreased antithrombin III survival with, 1984: June, 262

Septicemia, lung injury and, 1983: Dec., 719–744

Sequential testing. See Series testing.
Series testing, predictive value model in,
1982: Dec., 695-698
selection of, 1982: Dec., 871-890

short-term, functions of, 1982: Dec., 835–850

Serine protease(s), 1984: June, 211 interaction of antithrombin III with, 1984: June, 254–255

Serologic testing, in chlamydial respiratory infection, 1982: June, 377–379

in fungal respiratory infection, 1982: June, 332–339

in hepatitis, 1982: Mar., 245

in Legionella infection, 1982: June, 350–356

in *Pneumocystis* infection, 1982: June, 403–404

in viral respiratory infection, 1982: June, 386–387

preanalytic factors in, 1983: Sept., 535 Serotonin, in anaphylaxis, 1983: Dec., 620 in endotoxin-induced lung injury, 1983: Dec., 731

Serum antithrombin III, assays for, 1984: June, 265, 266

Serum inhibitory dilution test, 1984: Mar., 112

Sex chromatin tests, in diagnosis of endocrine diseases, 1984: Dec., 835–836

Sexual differentiation, disorders of, cytogenetic evaluation, 1984: Dec., 839–840 Sexually transmitted disease(s), chlamydial,

diagnosis of, 1982: June, 371–375 Shewhart criteria, for quality control data,

1983: Sept., 546 Shock, hemorrhagic, fluid management in, 1982: Mar., 35-63

Shock lung. See Respiratory distress syndrome, adult.

Sickle cell disease, erythrapheresis and, 1982: Mar., 101

Sjögren's syndrome, antibody markers of, 1983: Dec., 754–755

Skeletal injury, in battered child, 1983: June, 332–333

Skeletal remains, determination of identity from, 1983: June, 298

Skin, autoimmune disease of, 1983: Dec., 753–754

burn injury of. See Burn(s).

disorders, prostaglandins and, 1983: Dec., 703

effect of toxic plants on, 1984: Sept., 604

exposure of to toxins, treatment, 1984: Sept., 618-619

of infants, as route of entry for toxins, 1984: Sept., 471

Skin necrosis, in coumarin therapy for protein C disorders, 1984: June, 271 Skin testing, in diagnosis of occupational lung disease, 1984: Sept., 523–526

Skull injury, from firearms, 1983: June, 267–268, 287–288

in battered child, 1983: June, 333–334 in fire victims, 1983: June, 302

SLE. See Lupus erythematosus, systemic. Sleep apnea, vs. asphyxiation, in infants, 1983: June, 338–342

Slow-reacting substance of anaphylaxis (SRS-A), in anaphylaxis, 1983: Dec., 620-625 in endotoxin-induced lung injury, 1983: Dec., 728

production of, 1983: Dec., 681

Smoke inhalation, death from, 1983: June, 299–300

Soaps, ingestion of, 1984: Sept., 593 Sodium meclofenamate. See Meclofenamate

sodium.
Soft tissue lesions, aspiration biopsy of,

1984: Mar., 96Software, for laboratory information system,1983: Mar., 6–7

for microcomputers (appendix), 1983: Mar., 59–60

reliability, in laboratory information system, 1983: Mar., 170-171

security, in laboratory information system, 1983: Mar., 171–173

selection, in laboratory information system, 1983: Mar., 27 in user-designed system, 1983: Mar.,

43–45
Software applications, of microcomputer, in

clinical laboratory, 1983: Mar., 54-59 Software configuration, in laboratory infor-

mation system, 1983: Mar., 237 Software maintenance, in laboratory information system, 1983: Mar., 235 contract for, 1983: Mar., 33

Solubility, of toxic compounds in the environment, 1984: Sept., 453-454

Spare parts, for hardware, in laboratory information system, 1983: Mar., 168

Specificity, of screening tests, 1982: Sept., 640–642

Specimen(s), pathology, automated management of, 1983: Mar., 139–140 respiratory, evaluation of, 1982: June,

259–267
in *Pneumocystis* infection, 1982: June,

in Pneumocystis infection, 1982: June 396–398

in recovery of fungi, 1982: June, 323-324 in viral isolation, 1982: June, 384-386

transport of, 1982: June, 295–296 sputum. See Sputum. Spermidine, in malignant disease, 1982: Sept., 507–518

Spermine, in malignant disease, 1982: Sept., 507-518

Spherocyte(s), partial phagocytosis and, 1982: Mar., 215

Splenectomy, pretransplantation, 1983: Dec., 770

Spondylitis, ankylosing, HLA-B27 antigen and, 1982: Mar., 130–131

Sputum, specimen, in diagnosis of respiratory infection, 1982: June, 270–271 in tuberculosis, 1982: June, 311–312

macroscopic assessment of, 1982: June, 259–260

microscopic assessment of, 1982: June, 260–262

SRS-A. See Slow-reacting substance of anaphylaxis.

Stains and staining. See also specific stains, such as Gram's stain.

acid-fast, in tuberculosis, 1982: June, 311–312

in identification of *Chlamydia*, 1982: June, 377

in identification of *Legionella*, 1982: June, 356–357

in *Pneumocystis* infection, 1982: June, 396–403

Standard error, of percentage, 1982: Dec., 690

Staphylococcus aureus, susceptibility testing of, 1984: Mar., 111

Stat testing, 1983: Sept., 497–505. See also specific tests. approaches for, 1983: Sept., 498–500

instrumentation for, 1983: Sept., 501 setting priorities for, 1983: Sept., 504-505 Stem cell, collection, therapeutic, 1982:

Mar., 102–103 Steroid(s), anabolic, increased antithrombin III activity with, 1984: June, 263

Steroid hormone measurements, 1984: Dec., 817–833

Stomach, cancer of, diagnostic approach to, 1984: Mar., 26–28

Stool cultures, preanalytic factors in, 1983: Sept., 534

Storage lesion, blood, 1982: Mar., 4-6, 22-29

Streptococcus pneumoniae, susceptibility testing of, 1984: Mar., 111

Stress, effect on regulation of cortisol secretion, 1984: Dec., 685-686

Substrates, synthetic, in coagulation laboratory, 1984: June, 381-394

Sucrose density gradient ultracentrifugation, for hormone receptor measurement, 1984: Dec., 821–822

Sudden infant death, vs. asphyxiation, 1983: June, 338–342

Surgery, elective, crossmatch guidelines for, 1982: Mar., 172–173

excessive bleeding with, laboratory evaluation of, 1984: June, 298 Susceptibility testing, antimicrobial. See also antimicrobial susceptibility testing.

in anaerobic respiratory infection, 1982: June, 300–301

in Legionella infection, 1982: June, 363–365

mycobacterial, 1982: June, 314-315

Synergy testing, 1984: Mar., 113

Synovial inflammation, prostaglandins and, 1983: Dec., 702–706

Synthetic substrates, in coagulation studies, 1984: June, 381–394

System reliability, in automated clinical laboratory, 1983: Mar., 165-177

Systemic disease, excessive bleeding due to, evaluation of, 1984: June, 298–299

Systemic lupus erythematosus. See Lupus erythematosus, systemic.

T cell(s). See *Lymphocyte*(s). Tannins, overdose, 1984: Sept.. 613

Tattooing, around firearm entrance wound, 1983: June, 266–267

Technology, computer, in clinical laboratory, symposium on, 1983: Mar., 3-251. See also Computer information systems. medical, assessment of, 1983: Mar., 186-

Teeth, determination of identity from, 1983: June, 297–298

TENase, 1984: June, 310

523-538

Teratology, 1984: Sept., 464-467

Terminal deoxynucleotidyl transferase (TdT), in leukemia, 1982: Sept., 484–485

Test(ing), laboratory. See also Laboratory testing and under specific test. preanalytic variables in, 1983: Sept.,

'stat," 1983: Sept., 497-505

Test parameters, in assessing instrumentation needs, 1983: Sept., 427

Test threshold, 1984: Mar., 35

Testis, germ cell tumor of, markers for, 1982: Sept., 447–453 Therapeutic monitoring, in breast cancer,

1982: Sept., 527–528 in multiple myeloma, 1982: Sept., 536

in prostatic cancer, 1982: Sept., 531–532 Thermal injury. See *Burn injury*. Thermometers, ingestion of, 1984: Sept.,

Thin-layer chromatography. See Chromatographu.

Threshold approach, in multiple testing, 1982: Dec., 871–872

Thrombin, functions of, 1984: June, 208, 216

inactivation by antithrombin III, 1984: June, 248–250

endothelial cells in, 1984: June, 252–254

model of, 1984: June, 253-255

inhibition by plasma, nomenclature for, 1984: June, 246. See also Antithrombin. inhibition by protein C, 1984: June, 266–277

interaction with endothelial cells, 1984: June, 273

Thrombin time (TT), measurement of, 1984: June, 296

Thrombocyte(s). See Platelet(s).

Thromboembolic disease, due to hereditary antithrombin III deficiency, 1984: June, 255–257

disease, hereditary Factor VII deficiency associated with, 1984: June, 236

recurrent, hereditary disorders associated with, 1984: June, 245

Thrombomodulin, in coagulation, 1984: June, 216

Thromboplastin, bovine, quantitation of activated Factor VIIa by, 1984: June, 233

Thrombosis, deep venous, diagnosis and treatment of, fibrinopeptide A assays in, 1984: June, 363–380

due to protein C disorders, 1984: June, 271

Thrombotic disorders, dysfibrinogenemia and, 1984: June, 408

Thrombotic thrombocytopenic purpura, plasmapheresis and, 1982: Mar., 96

Thromboxane(s), in anaphylaxis, 1983: Dec., 622–623 in endotoxin-induced lung injury, 1983:

Dec., 724-725 in neutrophil stimulation, 1983: Dec.,

786-787 Thymoma, antibody markers of, 1983: Dec., 753

Thymus gland, aspiration biopsy of, 1984: Mar., 33

Thyroid, autoimmune disease of, 1983: Dec., 750–752

disorders, test selection in, 1982: Dec., 735–750, 797–798, 803–819

Thyroid binding capacity, estimates of, 1984: Dec., 659-660

Thyroid function tests, 1984: Dec., 657-668 algorithm for, 1984: Dec., 665-668 controversies in, 1984: Dec., 671-682 in euthyroid sick patients, 1984: Dec.,

664–665 Thyroid gland, aspiration cytology of, 1984: Mar., 92

diseases of, diagnostic approach, 1984: Dec., 655-670 Thyroid hormones, production of, 1984: Dec., 655–657

Thyroid nuclear receptors, 1984: Dec., 828–829

Thyroid-stimulating hormone, hypersecretion of by pituitary adenomas, 1984: Dec., 651–652

mass effects of pituitary tumors on, 1984: Dec., 646–647

measurement of, 1984: Dec., 658–659 Thyroiditis, chronic, thyroid function tests in, 1984: Dec., 663

Hashimoto's, diagnosis of, 1984: Mar., 92

Thyrotropin, measurement of, 1984: Dec., 658–659

Thyrotropin receptor antibody assays, 1984: Dec., 829

Thyroxine, free, assays for, controversies in, 1984: Dec., 671–678 index, controversies in, 1984: Dec., 673–674

Time series analysis, of markers, in monitoring cancer, 1982: Sept., 671-672

Time, of laboratory tests, to monitor disease, 1982: Dec., 851-870

Tissue factor, in blood coagulation, 1984: June, 216, 223–224

Tissue immunopathology, symposium on, 1983: Dec., 577–817

Tissue polypeptide antigen (TPA), in breast cancer, 1982: Sept., 547-548

Toiletries, ingestion of, 1984: Sept., 592–593 Tolerance, to antibiotics, 1984: Mar., 112

Toluene, ingestion of, 1984: Sept., 597 Tourniquet test, 1984: June, 293 Toxic and biological hazards, 1983: Sept.,

Toxic and biological hazards, 1983: Sept., 472
Toxic compounds, in environment, behavior

of, 1984: Sept., 451–459
Toxicologic analysis, 1983: June, 367–384,

385–396
in fire deaths, 1983: June, 305–306
in product liability deaths, 1983: June

in product liability deaths, 1983: June, 400–401 specimens for, 1983: June, 368

Toxicology, dose-response relationship in, 1984: Sept., 507-519 forensic, 1983: June, 367-384, 385-396

reproductive, 1984: Sept., 461–467 Toxicology laboratory, 1983: June, 367–384, 385–396

Toxins. See Chemicals, toxic; and under specific agent.

Trace evidence, 1983: June, 355–365. See also Evidence.

Training in pathology, fifth-year controversy, 1984: Mar., 185–200

Transferrin, levels, in assessment of iron status, 1982: Dec., 756-757

Transfusion, blood, in cardiovascular surgery, 1982: Mar., 75–82

in heart surgery, 1982: Mar., 65–85 pretransplantation, 1983: Dec., 770 compatibility testing in, 1982: Mar.,

169-179 hemolytic reactions in, 1982: Mar., 79, 221-231

in autoimmune hemolytic anemia, 1982: Mar., 193–210

in hemolytic disease of newborn, 1982: Mar., 118

massive, 1982: Mar., 21-34

of blood components, 1982: Mar., 3-19 HLA typing in, 1982: Mar., 129-130 reactions, 1982: Mar., 78-79, 221-231 transmission of hepatitis and, 1982: Mar., 233-252

Transplantation, of kidney, HLA typing in, 1982: Mar., 125-129

of marrow, HLA typing in, 1982: Mar., 128-129

organ, immunologic principles and, 1983: Dec., 763-778

Transtracheal aspiration (TTA), in anaerobic respiratory infection, 1982: June, 292–293

Treatment thresholds, 1984: Mar., 33 Triiodothyronine, measurement of, 1984: Dec., 658

Triiodothyronine-uptake test, 1984: Dec., 659–660

Tuberculosis, laboratory diagnosis of, 1982: June, 305–319

Tuftsin, deficiency, in neutrophil dysfunction, 1983: Dec., 789

Tumor(s), fibrous, of pleura, electronmicroscopic diagnosis of, 1984: Mar., 130–137 germ cell, markers for, 1982: Sept., 431–458

pituitary, 1984: Dec., 643-654 Wilms', 1984: Mar., 159

Tumor marker(s). See also under specific markers, such as Carcinoembryonic antigen, or under specific disease.

criteria for clinical utility, 1982: Sept., 511-514

enzyme, characteristics of, 1982: Sept., 493–494 in breast cancer, 1982: Sept., 543–565

assessment of, 1982: Sept., 657-678 in malignant disease, symposium on,

1982: Sept., 413-678 Turner syndrome, cytogenetic evaluation, 1984: Dec., 837-839

Type and screen, in pretransfusion testing, 1982: Mar., 169–179 Universal donor blood, 1982: Mar., 183-184 University of Arizona microbiology system, 1983: Mar., 107-109 Urinary elimination, of xenobiotics, in chil-

dren, 1984; Sept., 471

Urinary hormone assay, 1983: Sept., 529 Urine, alcohol levels in, 1983: June, 388,

assays, in Legionella infection, 1982: June, 361-362

catecholamine and catecholamine catabolites in, in diagnosis of pheochromocytoma, 1984: Dec., 706-710 cultures, preanalytic factors in, 1983:

Sept., 532

drug levels in, 1983: June, 370-371 glucorticoids in, in diagnosis of, of hypercortisolism, 1984: Dec., 698-700

specimens, collection and handling of, 1983: Sept., 532

Urine osmolality to serum osmolality relationship, in assessment of antidiuretic hormone function, 1984: Dec., 739-740 Urogenital tract, cancer, CK1 activity in,

1982: Sept., 497-499

Urticarial transfusion reactions, 1982: Mar., 221-227

User design, of laboratory information system, 1983: Mar., 29, 35-50

Values, changing, coping with, 1983: Sept., 558-560

Vascular injury, hemostatic process following, 1984: June, 207-209

Vendor(s), of anatomic pathology software, 1983: Mar., 143-144 selection, for laboratory information sys-

tem, 1983: Mar., 19-34 Venous thrombosis, deep, blood tests for,

1984: June, 364 diagnosis and treatment of, fibrinopep-

tide A assays in, 1984: June, 363-380 Ventricular fibrillation, in electrical injury,

1983: June, 347, 349, 352 Viral hepatitis, platelet function in, 1984: June, 421

Virus(es), in breast cancer, 1982: Sept., 546-547

respiratory infection, laboratory diagnosis of, 1982: June, 383-391

Vitamin D, measurement of, in assessment of mineral metabolism, 1984: Dec., 770-771

Vitamin K, deficiency of, Factor VII deficiency with, 1984: June, 238 role in coagulation, 1984: June, 210-214 treatment of, 1984: June, 239

Vitamins, ingestion of, 1984: Sept., 595 Vitreous humor, alcohol levels in, 1983: June, 387-388, 393

drug levels in, 1983: June, 369

Voice entry devices, in interactive reporting systems, 1983: Mar., 142-143

Volatile oil intoxication, 1984: Sept., 610-611

von Willebrand disease, 1984: June, 303-317

abnormalities associated with, 1984: June, 309

bleeding time determination in, 1984: June, 320

classification of, 1984: June, 308-310 genetic counseling in, 1984: June, 310 inheritance of, 1984: June, 308-309 laboratory diagnosis of, 1984: June, 330 pathogenesis of, 1984: June, 304

pathophysiology of, 1984: June, 324-328 platelet-type, 1984: June, 319-331 clinical features of, 1984: June, 319-320

Factor VIII: C activity in, 1984: June,

laboratory results in, 1984: June, 320-324

platelet aggregation in, 1984: June, 324-326

platelet binding in, 1984: June, 326 platelet count in, 1984: June, 320 platelet function studies in, 1984: June, 321

platelet membrane studies in, 1984: June, 327-328

treatment of, 1984: June, 328 treatment of, 1984: 311-312

von Willebrand factor, binding to platelets, 1984: June, 306 polymers of, abnormalities of, 1984: June,

role in hemostasis, 1984: June, 305-308

tissue localization of, 1984: June, 305

Wastes, hazardous, disposal of, 1983: Sept., 477-480

Water load test, in assessment of antidiuretic hormone function, 1984: Dec., 741-742

Water metabolism, hormonal disorders of, assessment of, 1984: Dec., 729-744 Weapons, projectile. See Firearm(s).

White blood cell(s). See Leukocyte(s); Neutrophil(s).

Whole blood, transfusion of, 1982: Mar.,

in critically ill, 1982: Mar., 52 Wilms' tumor, 1984: Mar., 159

- Word processors, 1983: Mar., 16 in anatomic pathology, 1983: Mar., 140–142
- Workflow analysis, in clinical laboratory, 1983: Mar., 11–12, 79–100, 236
- Work-in-process, in computerized laboratory, 1983: Mar., 92–98
- Workload analysis, in laboratory, 1983: Sept., 424
- Workload Recording Method, 1983: Sept., 556–562
- Wounds, firearm. See Firearm wounds. Wound ballistics, 1983: June, 260-261
- Xylene, ingestion of, 1984: Sept., 597